* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4	OCT 03	MATHDI removed from STN
NEWS 5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 8	OCT 27	Free KWIC format extended in full-text databases
NEWS 9	OCT 27	DIOGENES content streamlined
NEWS 10	OCT 27	EPFULL enhanced with additional content
NEWS 11	NOV 14	CA/CAplus - Expanded coverage of German academic research
NEWS 12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS 13	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 14	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 17	DEC 16	MARPATprev will be removed from STN on December 31, 2005

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:00:31 ON 20 DEC 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:00:36 ON 20 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6
DICTIONARY FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading structure

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 18:03:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 18:03:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

L3 12 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	163.48	163.69

FILE 'HCAPLUS' ENTERED AT 18:04:02 ON 20 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Dec 2005 VOL 143 ISS 26
FILE LAST UPDATED: 19 Dec 2005 (20051219/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 1 L3

=> d l4, ibib abs hitstr, 1

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:2698 HCAPLUS
DOCUMENT NUMBER: 140:59519
TITLE: Preparation of (biphenylylalkoxy)- and [(phenylpyridyl)alkoxy]-substituted phenylalkanoic acids and phenoxyalkanoic acids as hPPAR activators for treatment of cardiovascular disease and related disorders
INVENTOR(S): Hamlett, Christopher Charles Frederick; Bell, Richard; Beswick, Paul John; Gosmini, Romain Luc Marie; King, Nigel Paul; Patel, Vipulkumar Kantibhai
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000315	A1	20031231	WO 2003-EP6415	20030618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2487909	AA	20031231	CA 2003-2487909		20030618
EP 1513526	A1	20050316	EP 2003-738056		20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003011931	A	20050405	BR 2003-11931		20030618
JP 2005534672	T2	20051117	JP 2004-514761		20030618
NO 2004005328	A	20050309	NO 2004-5328		20041203
PRIORITY APPLN. INFO.:			GB 2002-14149	A	20020619
			WO 2003-EP6415	W	20030618

OTHER SOURCE(S): MARPAT 140:59519
GI



AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = O or (CH2)n; n = 0-2; R3 R4 = independently H, alkyl, OMe, CF3, allyl, or halo; X1 = O, S, SO2, SO, or CH2; R5 and R6 = independently H, (halo)alkyl, or alkoxyalkyl; or CR5R6 = cycloalkyl; R7 = (un)substituted Ph or 6-membered heteroaryl; and pharmaceutically acceptable salts, solvates, and hydrolyzable esters thereof] were prepd. as human peroxisome proliferator activated receptor (hPPAR) activators. For example, a mixt. of 3-(bromomethyl)-4'-(trifluoromethyl)biphenyl, Et (4-mercapto-2-methylphenoxy)acetate, and polymer-supported diisopropylethylamine in DCM was stirred at room temp. overnight to give the thioether. Sapon. of the ester with aq. NaOH in THF and acidification afforded II. Compds. of the invention showed at least 50% activation of hPPARδ relative to the pos. control at concns. of 10-7 M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, or anorexia nervosa (no data).

IT **638215-86-8P**, [[4-[[(1R)-1-[6-(4-Cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-91-5P**, [[4-[[(1S)-1-[6-(4-Cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-96-0P**, [[4-[[(1R)-1-[6-(4-

Cyano-3-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-02-1P**, [[4-[[(1R)-1-[6-(3-Chloro-4-cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-03-2P**, [[4-[[(1R)-1-[6-(4-Cyano-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-05-4P**, [[4-[[(1R)-1-[6-(4-Cyano-2-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-06-5P**, [[4-[[(1R)-1-[6-(4-Cyano-2-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-10-1P**, [[4-[[(1S)-1-[6-(4-Cyano-3-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-16-7P**, [[4-[[(1S)-1-[6-(3-Chloro-4-cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-17-8P**, [[4-[[(1S)-1-[6-(4-Cyano-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-19-0P**, [[4-[[(1S)-1-[6-(4-Cyano-2-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-20-3P**, [[4-[[(1S)-1-[6-[4-Cyano-3-(methyloxy)phenyl]-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hPPAR activator; prepn. of (aryloxy)phenylalkanoic acids and (aryloxy)phenoxyalkanoic acids as hPPAR activators for treatment of cardiovascular disease and related disorders)

RN 638215-86-8 HCAPLUS

CN Acetic acid, [4-[(1R)-1-[6-(4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-91-5 HCAPLUS

CN Acetic acid, [4-[(1S)-1-[6-(4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-96-0 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-3-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-02-1 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(3-chloro-4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-03-2 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-3-methylphenyl)-2-pyridinyl]-2-

ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-05-4 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-2-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-06-5 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-2-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-10-1 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-3-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-16-7 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(3-chloro-4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-17-8 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-3-methylphenyl)-2-pyridinyl]-2-

ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-19-0 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-2-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-20-3 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-3-methoxyphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.39	171.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

FILE 'CAOLD' ENTERED AT 18:04:25 ON 20 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 18:00:31 ON 20 DEC 2005)

FILE 'REGISTRY' ENTERED AT 18:00:36 ON 20 DEC 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 12 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 18:04:02 ON 20 DEC 2005
L4 1 S L3

FILE 'CAOLD' ENTERED AT 18:04:25 ON 20 DEC 2005

=> s l3
L5 0 L3

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.43 171.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -0.73

FILE 'REGISTRY' ENTERED AT 18:04:30 ON 20 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6
DICTIONARY FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading structure

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
NEWS  2           "Ask CAS" for self-help around the clock
NEWS  3  SEP 09   ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS  4  OCT 03   MATHDI removed from STN
NEWS  5  OCT 04   CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                  to core patent offices
NEWS  6  OCT 13   New CAS Information Use Policies Effective October 17, 2005
NEWS  7  OCT 17   STN(R) AnaVist(TM), Version 1.01, allows the export/download
                  of CAplus documents for use in third-party analysis and
                  visualization tools
NEWS  8  OCT 27   Free KWIC format extended in full-text databases
NEWS  9  OCT 27   DIOGENES content streamlined
NEWS 10  OCT 27   EPFULL enhanced with additional content
NEWS 11  NOV 14   CA/CAplus - Expanded coverage of German academic research
NEWS 12  NOV 30   REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
                  spectral property data
NEWS 13  DEC 05   CASREACT(R) - Over 10 million reactions available
NEWS 14  DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15  DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16  DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 17  DEC 16 MARPATprev will be removed from STN on December 31, 2005

NEWS EXPRESS  DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
              CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
              V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
              http://download.cas.org/express/v8.0-Discover/

NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:08:19 ON 20 DEC 2005

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:08:25 ON 20 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
```

provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6
DICTIONARY FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=>
Uploading structure

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

=> s l1
SAMPLE SEARCH INITIATED 16:11:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     2441 TO ITERATE

 81.9% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        45857 TO    51783
PROJECTED ANSWERS:             951 TO     1977

L2           50 SEA SSS SAM L1

=> s l2 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:11:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    49782 TO ITERATE
```

100.0% PROCESSED 49782 ITERATIONS 1449 ANSWERS
SEARCH TIME: 00.00.01

L3 1449 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 163.05 163.26

FILE 'HCAPLUS' ENTERED AT 16:11:25 ON 20 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 20 Dec 2005 VOL 143 ISS 26
FILE LAST UPDATED: 19 Dec 2005 (20051219/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3/thu
239 L3
738046 THU/RL
L4 102 L3/THU
(L3 (L) THU/RL)

=> s l4 and pd < july 2002
22609159 PD < JULY 2002
(PD<20020700)
L5 34 L4 AND PD < JULY 2002

=> d l5, ibib abs fhitstr, 1-34

L5 ANSWER 1 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN
Full Text | Citing References

ACCESSION NUMBER: 2003:270940 HCAPLUS
DOCUMENT NUMBER: 139:286120
TITLE: Pharmacology of a selective peroxisome proliferator-activated receptor δ agonist, GW501516, in obese dyslipidemic primates
AUTHOR(S): Oliver, William, Jr.; Sternbach, Dan; Hansen, Barbara; Willson, Timothy
CORPORATE SOURCE: GlaxoSmithKline, Research Triangle Park, NC, 27709, USA

SOURCE: Medical Science Symposia Series (2002), 18(Peroxisome Proliferator Activated Receptors), 131-134
CODEN: MSSYEI; ISSN: 0928-9550
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To evaluate the therapeutic potential of a PPARδ agonist the authors developed a subtype selective small mol. ligand using combinatorial chem. and structure based drug design. GW501516 is a high affinity ligand in a human PPARδ binding assay with Ki = 1.1 ? 0.1 nM with a >1,000-fold selective for PPARδ over the PPARα and γ subtypes. The obese rhesus is a primate model of human metabolic disease that develops spontaneous adult-onset obesity on std. low fat diets and shows a high risk of developing overt diabetes. The prediabetic state of these primates displays many of the same features of human metabolic syndrome X, including dyslipidemia, insulin resistance, central obesity, hyperinsulinemia, and hypertension. Obese rhesus monkeys received increasing doses of GW501516 (0.1, 0.3, 1, and 3 mg/kg, bid) with each dose administered over a 4-wk period and clin. chemistries examd. The results of the study demonstrated that PPARδ agonists are likely to have beneficial effects on the lipid triad of low HDLc, increased proportions of small dense LDLc, and elevated triglycerides through a mechanism that increases cholesterol flux from peripheral tissues. These findings further support the value of PPARδ agonists and GW501516 specifically, as therapeutic agents for decreasing the incidence of cardiovascular disease assocd. with metabolic syndrome X.

IT **317318-70-0**, GW501516
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmacol. of a selective peroxisome proliferator-activated receptor δ agonist, GW501516, in obese dyslipidemic primates)

RN 317318-70-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:487541 HCAPLUS
DOCUMENT NUMBER: 137:63239
TITLE: Thia- and oxazoles and their use as hPPAR delta

agonists

INVENTOR(S): Beswick, Paul John; Patel, Vipulkumar; Sierra, Michael Lawrence

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050048	**A1**	**20020627**	**WO 2001-EP14887**	**20011218**
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002029669	A5	20020701	AU 2002-29669	20011218
EP 1343772	A1	20030917	EP 2001-990571	20011218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004102493	A1	20040527	US 2003-451307	20031117

PRIORITY APPLN. INFO.:

GB 2000-31109	A	20001220
WO 2001-EP14887	W	20011218

OTHER SOURCE(S): MARPAT 137:63239

GI



I

AB I (e.g. [4-[1,1-difluoro-3-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propyl]-2-methylphenoxy]acetic acid) or pharmaceutically acceptable salts and solvates thereof are claimed. R1 and R2 are independently H or C1-3alkyl, m is 0-3; X1 is NH, NCH3, O, S; R3, R4 and R5 are independently H, CH3, CF3, OCH3, allyl or halogen; X2 is (CR10R11)n wherein n is 1 or 2; R10 and R11 independently represent H, F or C1-16alkyl; R26 and R27 are independently H, C1-3 alkyl or R26 and R27 together with the C atom to which they are bonded form a 3-5 membered cycloalkyl ring. R6 and R7 independently represent H, F or C1-16alkyl; R9 is C1-6alkyl or CF3; one of Y and Z is N, the other is S or O; each R8 independently represents CF3, OCH3, CH3 or halogen; y is 0-5. Use of I for the manuf. of a medicament for the prevention or treatment of a hPPAR (human peroxisome proliferator activated receptor)-mediated disease or condition, such as dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, type II diabetes mellitus, type 1 diabetes, insulin resistance hyperlipidemia, obesity, anorexia, bulimia, inflammation and anorexia nervosa. Binding and transfection

assays are described but no results are given. Although the methods of prepn. are not claimed, 35 example prepns. of intermediates and claimed compds. are included.

IT **439135-02-1P**, [2-Methyl-4-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethyl]phenoxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(thia- and oxazoles and use as hPPAR delta agonists)

RN 439135-02-1 HCAPLUS

CN Acetic acid, [2-methyl-4-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | More References

ACCESSION NUMBER: 2002:449665 HCAPLUS
DOCUMENT NUMBER: 137:20379
TITLE: Preparation of 1,2,4-oxadiazoles as hPPAR alpha agonists
INVENTOR(S): Gellibert, Francoise Jeanne; Liu, Kevin Guangcheng
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046174	A1	20020613	WO 2001-GB5400	20011206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430847	AA	20020613	CA 2001-2430847	20011206
AU 2002020902	A5	20020618	AU 2002-20902	20011206

EP 1355890	A1	20031029	EP 2001-999566		20011206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
ZA 2003004312	A	20041013	ZA 2003-4312		20030602
NO 2003002582	A	20030807	NO 2003-2582		20030606
BR 2003002137	A	20050322	BR 2003-2137		20030613
US 2004132787	A1	20040708	US 2004-433807		20040108
PRIORITY APPLN. INFO.:			GB 2000-29974	A	20001208
			WO 2001-GB5400	W	20011206

OTHER SOURCE(S): MARPAT 137:20379
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; X1 = O, S; X2 = O, S; n = 1-3; one of Y and Z = N, and the other = O; R1, R2 = halo, H, CF3, OMe, alkyl; R3 = halo, CF3, alkyl; R4, R5 = H, alkyl; Y = 0-5] and their pharmaceutically acceptable salts, solvates and hydrolysable esters, were prepd. Thus, reacting II with III (prepns. given) in the presence of K2CO3 in Me2CO (42%) followed by ester hydrolysis (99%) afforded the acid IV which showed EC50 of 0.024 μM against hPPAR alpha.

IT **435303-01-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1,2,4-oxadiazoles as hPPAR alpha agonists)

RN 435303-01-8 HCAPLUS
CN Propanoic acid, 2-[4-[[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]methoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Print References

ACCESSION NUMBER:	2002:368462 HCAPLUS
DOCUMENT NUMBER:	136:386118
TITLE:	Preparation of (phenylalkyl)-1H-[1,2,4]triazolones as PPARα agonists for treatment of cardiovascular disease associated with Syndrome X and related conditions
INVENTOR(S):	Mantlo, Nathan Bryan; Collado Cano, Ivan; Dominianni, Samuel James; Etgen, Garret Jay, Jr.; Garcia-Paredes, Cristina; Johnston, Richard Duane; Letourneau, Michael Edward; Martinelli, Michael John; Mayhugh, Daniel Ray; Saeed, Ashraf; Thompson, Richard Craig; Wang, Xiadong; Coffey, David Scott; Schmid, Christopher Randall; Vicenzi, Jeffrey Thomas; Xu, Yanping

PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 388 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002038553	**A2**	**20020516**	**WO 2001-US42928**		**20011109**
WO 2002038553	A3	20030501			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2421154	**AA**	**20020516**	**CA 2001-2421154**		**20011109**
AU 2002028592	**A5**	**20020521**	**AU 2002-28592**		**20011109**
EP 1335908	A2	20030820	EP 2001-989704		20011109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001014986	A	20030923	BR 2001-14986		20011109
JP 2004513166	T2	20040430	JP 2002-541088		20011109
ZA 2003002517	A	20040630	ZA 2003-2517		20030331
NO 2003002059	A	20030624	NO 2003-2059		20030508
HR 2003000365	A1	20030831	HR 2003-365		20030508
US 2004102500	A1	20040527	US 2003-415673		20030911
PRIORITY APPLN. INFO.:			US 2000-247317P	P	20001110
			WO 2001-US42928	W	20011109

OTHER SOURCE(S): MARPAT 136:386118
GI



AB Title compds. I [wherein R1 = H or (un)substituted alkyl, (hetero)arylalkyl, cycloalkylarylalkyl, CH2COR17R18; R17 = O or NH; R18 = (un)substituted benzyl; W = O or S; R2 = H or (un)substituted

(cyclo)alkyl, allyl, (hetero)arylalkyl, sulfonamido, amido, or OR10; R10 = H or alkyl; X = (un)substituted alkylene linker wherein 1 C may be replaced with O, NH, or S; Y = C, O, S, NH, or a single bond; E = H, CR3R4A; A, (un)substituted (CH2)nCO2C19, (aryl)alkyl, allyl, thioalkyl, thioaryl, alkoxyaryl, alkoxyalkyl, aminoaryl, or aminoalkyl; n = 0-3; A = carboxy, alkylnitrile, carboxamide, or (un)substituted sulfonamide, acylsulfonamide, or tetrazole; R3 = H, alkyl, or alkoxy; R4 = H, halo, or (un)substituted (cyclo)alkyl, alkoxy, arylalkyl, or Ph; or CR3R4 = cycloalkyl; R19 = H or (un)substituted arylmethyl or alkyl; R8 = independently H, alkyl, alkenyl, or halo; R9 = independently H, alkenyl, halo, allyl, OR10, or (un)substituted alkyl or (hetero)aryl; R10 = independently H or alkyl] were prepd. as peroxisome proliferator activated receptor alpha (PPARα) agonists. For example, condensation of 3-chlorobenzaldehyde with 4-(4-hydroxyphenyl)butyrylhydrazide (p-TsOH, i-PrOH), followed by redn. (NaBH3CN, THF, AcOH, i-PrOH), treatment with n-PrNCO (THF), and cyclization (KOH, MeOH), afforded 2-(3-chlorobenzyl)-5-[3-(4-hydroxyphenyl)propyl]-4-propyl-3H-triazolin-3-one. Addn. of tert-Bu 2-bromoisobutyrate (K2CO3, DMF) and deesterification (TFA, CH2Cl2) gave II. I bound to PPARα receptors with IC50 values of ? 100 nM and demonstrated PPARα cotransfection efficacy in CV-1 cells of ? 50%. Significant redn. in RQ in female Ay mice [0.864 ? 0.013 (control) vs. 0.803 ? 0.007 (treated); p < 0.001] was obsd. at doses of 50 mg/kg of I. Addnl., treated animals displayed significantly higher rates of energy expenditure than control animals (17.40 ? 0.49 vs. 13.62 ? 0.26 kcal/kg/h, resp.). Thus, I are useful for the prevention and/or treatment of cardiovascular disease assocd. with Syndrome X, hyperinsulemia, hypertension, elevated body wt., elevate triglycerides, and elevated LDL.

IT **425672-17-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); **THU (Therapeutic use)**; **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(cardiovascular agent; prepn. of (phenylalkyl)triazolones as PPARα agonists for treatment of cardiovascular disease assocd. with Syndrome X and related conditions)

RN 425672-17-9 HCAPLUS
CN Propanoic acid, 2-[4-[2-[4,5-dihydro-5-oxo-4-propyl-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]ethyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Other References

ACCESSION NUMBER: 2002:275829 HCAPLUS
DOCUMENT NUMBER: 136:304064
TITLE: Medicaments of peroxisome proliferator-activated receptor (PPAR) δ for treatment of inflammatory diseases
INVENTOR(S): Buchan, Kevin William

PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002028434	**A2**	**20020411**	**WO 2001-GB4373**		**20011001**
WO 2002028434	A3	20020815			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2001092046	**A5**	**20020415**	**AU 2001-92046**		**20011001**
EP 1324774	A2	20030709	EP 2001-972266		20011001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004510750	T2	20040408	JP 2002-532258		20011001
US 2005131035	A1	20050616	US 2003-398629		20011001
PRIORITY APPLN. INFO.:			GB 2000-24361	A	20001005
			WO 2001-GB4373	W	20011001

OTHER SOURCE(S): MARPAT 136:304064

AB Methods of prevention or treatment of inflammatory diseases or conditions, the use of PPAR delta activators in such methods, and methods for the identification of compds. useful in such treatment. PPAR δ agonist, 2-[2-methyl-4-[[[4-methyl-2-[4-(trifiuoromethyl)phenyl]-1,3-thiazol-5-yl]methyl]sulfanyl]phenoxy]acetic acid (prepn. given), inhibited the activity and expression of inducible nitric oxide synthase.

IT **317318-70-0P**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicaments of peroxisome proliferator-activated receptor (PPAR) δ for treatment of inflammatory diseases)

RN 317318-70-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Sharing References

ACCESSION NUMBER: 2002:275828 HCAPLUS
DOCUMENT NUMBER: 136:289090
TITLE: Synthesis of PPARδ activators for treatment of diseases or conditions where inhibition of nitric oxide synthase and tumor necrosis factor is desirable
INVENTOR(S): Buchan, Kevin William
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028433	**A2**	**20020411**	**WO 2001-GB4370**	**20011002**
WO 2002028433	A3	20020815		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001092044	**A5**	**20020415**	**AU 2001-92044**	**20011002**
EP 1324773	A2	20030709	EP 2001-972264	20011002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004510749	T2	20040408	JP 2002-532257	20011002
US 2004029938	A1	20040212	US 2003-398417	20030821
PRIORITY APPLN. INFO.:			GB 2000-24362	A 20001005
			WO 2001-GB4370	W 20011002

OTHER SOURCE(S): MARPAT 136:289090

AB Methods of prevention or treatment of diseases or conditions where inhibition of NO synthase and/or TNF is desirable, the use of PPAR delta activators in such methods and methods for the identification of compds. useful in such treatment.

IT **317318-70-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU**

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of PPARδ activators for treatment of diseases or conditions where inhibition of nitric oxide synthase and tumor necrosis factor is desirable)

RN 317318-70-0 HCAPLUS

CN Acetic acid, [2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:171871 HCAPLUS

DOCUMENT NUMBER: 136:232294

TITLE: Oxazolyl-aryloxyacetic acid derivatives and thiazole analogs and their use as PPAR agonists, e.g., as antidiabetics and hypolipidemics

INVENTOR(S): Brooks, Dawn Alisa; Connor, Scott Eugene; Dominianni, Samuel James; Godfrey, Alexander Glenn; Gossett, Lann Stacy; Rito, Christopher John; Tripp, Allie Edward; Warshawsky, Alan M.; Winneroski, Leonard Larry; Zhu, Guoxin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 246 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018355	A1	20020307	WO 2001-US22615	20010823
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420178	AA	20020307	CA 2001-2420178	20010823
AU 2001084658	A5	20020313	AU 2001-84658	20010823

EP 1313715		A1	20030528	EP 2001-963732		20010823
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2004509084		T2	20040325	JP 2002-523473		20010823
US 2004024034		A1	20040205	US 2003-343474		20030129
US 2005250825		A1	20051110	US 2005-181640		20050714
PRIORITY APPLN. INFO.:				US 2000-227233P	P	20000823
				WO 2001-US22615	W	20010823
				US 2003-343474	A3	20030129

OTHER SOURCE(S): MARPAT 136:232294
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title oxazoles I and their pharmaceutically acceptable salts, solvates, and hydrates are disclosed [wherein R1 = (un)substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl, or cycloalkyl-alkyl; R2 = H, alkyl, or haloalkyl; n = 2, 3, or 4, with the resultant polymethylene chain optionally contg. a carbon-carbon double bond; W = O or S; Y = (un)substituted phenylene, naphthylene, or 1,2,3,4-tetrahydronaphthylene; R3 = H, alkyl, or haloalkyl; R4 = H, alkyl, haloalkyl or (un)substituted PhCH2; provided that when R3 = R4 = H, then R2 = alkyl or haloalkyl; R5 = H, alkyl, aminoalkyl]. Approx. 120 examples are given. One example of a thiazole analog is also given. The compds. are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus. For instance, 2-(3-bromophenyl)-4-(chloromethyl)-5-methyloxazole (prepd. in 2 steps) underwent cyanation, hydrolysis to an acid, redn. to an alc., tosylation, and etherification with the corresponding phenol deriv. to give intermediate bromide II. The latter compd. underwent Pd-catalyzed ethynylation, hydrogenation of the ethynyl group, and alk. hydrolysis, to give title compd. III. This compd. bound to human PPARα and PPARγ receptors in vitro with IC50 values of 31 and 219 nM, resp., vs. values of 94,500 and 1180 for troglitazole, and 68,000 and 125,000 for fenofibric acid. At 30 mg/kg orally in mice (transgenic for human apoAI), III gave a 74.3% redn. in serum triglycerides and a 180% increase in high-d. lipoprotein cholesterol, vs. 41% and 48% for fenofibrate. III also gave complete normalization of blood glucose in diabetic mice at 30 mg/kg orally.

IT **403610-21-9P**, 2-Methyl-2-[4-(5-methyl-2-phenyloxazol-4-ylmethoxy)phenoxy]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of oxazolyl-aryloxyacetic acid derivs. and thiazole analogs and their use as PPAR agonists)

RN 403610-21-9 HCAPLUS
CN Propanoic acid, 2-methyl-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Click to Refer Brides

ACCESSION NUMBER: 2002:107062 HCAPLUS
DOCUMENT NUMBER: 136:145204
TITLE: Fatty acid synthase inhibitors
INVENTOR(S): Christensen, Siegfried B., IV; Daines, Robert A.; Lee, Jinhwa; Xiang, Jian-Ning
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009651	**A2**	**20020207**	**WO 2001-US24366**	**20010802**
WO 2002009651	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1322331	A2	20030702	EP 2001-963783	20010802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004505030	T2	20040219	JP 2002-515206	20010802
PRIORITY APPLN. INFO.:			US 2000-222683P	P 20000802
			WO 2001-US24366	W 20010802

OTHER SOURCE(S): MARPAT 136:145204

AB This invention relates to the use of compds. as inhibitors of the fatty acid synthase FabH. This invention further comprises novel compds. and pharmaceutical compns. contg. these compds. and their use as FabH inhibitors that are useful as antibiotics for the treatment of Gram pos. and Gram neg. bacterial infections.

IT **395067-29-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(fatty acid synthase FabH inhibitors for use in treatment of bacterial infections)

RN 395067-29-5 HCAPLUS

CN Benzeneacetic acid, α-[4-[(2,6-dichlorophenyl)methoxy]phenoxy]-

(9CI) (CA INDEX NAME)



L5 ANSWER 9 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:878334 HCAPLUS
DOCUMENT NUMBER: 136:160852
TITLE: 7-Substituted 5-Amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A Adenosine Receptor Antagonists: A Study on the Importance of Modifications at the Side Chain on the Activity and Solubility
AUTHOR(S): Baraldi, Pier Giovanni; Cacciari, Barbara; Romagnoli, Romeo; Spalluto, Giampiero; Monopoli, Angela; Ongini, Ennio; Varani, Katia; Borea, Pier Andrea
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Ferrara, Ferrara, I-44100, Italy
SOURCE: Journal of Medicinal Chemistry (**2002**), 45(1), 115-126
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:160852

AB It was demonstrated in the early 1990s that adenosine exerts many physiol. functions through the interaction with four different receptors, named A1, A2A, A2B, and A3. In the past few years, our group has been involved in the development of A2A antagonists, which led to the synthesis of SCH 58261 , the first potent and selective adenosine A2A antagonist, which has been widely used as a ref. compd. In this paper, we present an extended series of pyrazolotriazolopyrimidines synthesized with the aim to investigate the influence of the substitutions on the pyrazole ring. The choice of the substituents was based on their capability to improve water soly. while retaining high affinity and selectivity at the human A2A adenosine receptor subtype. In this series, some structural characteristics that are important for activity, i.e., tricyclic structure, free amino group at 5-position, furan ring, and substituent at 7-position on the pyrazole moiety, have been maintained. We focused our attention on the nature of the Ph ring substituent to improve water soly. Following this strategy, we developed new compds. with good affinity and selectivity for A2A adenosine receptors, such as aminophenylpropylfuranylpyrazolotriazolopyrimidinylamine (Ki 0.22; hA1/hA2A ratio = 9818; Rm = 3.4), aminofuranylpyrazolotriazolopyrimidinylethylhydroxybenzamidine (Ki 0.18 nM; hA1/hA2A ratio = 994; Rm = 2.8), aminophenylethylfuranylpyrazolotriazolopyrimidinylamine (Ki 0.13 nM; hA1/hA2A ratio = 4430; Rm = 3.6), and aminofuranylpyrazolotriazolopyrimidinylpropylhydroxymethylbenzodioxolylmethanol (Ki 0.19 nM; hA1/hA2A ratio = 2273; Rm = 2.7). All the new synthesized compds. have no significant interaction with either A2B or A3 receptor subtypes. This new series of compds. deeply enlightens some structural requirements to display high affinity and selectivity for the A2A adenosine receptor subtype, although our goal of identifying new compds. with increased water soly. was not completely achieved. On this basis, other strategies will be devised to

improve this class of compds. with a profile that appears to be promising for treatment of neurodegenerative disorders, such as Parkinson's disease.

IT **396124-31-5P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted aminofurylpyrazolotriazolopyrimidines as adenosine receptor antagonists)

RN 396124-31-5 HCAPLUS

CN Acetic acid, [4-[2-[5-amino-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | CHNG References

ACCESSION NUMBER: 2001:868414 HCAPLUS
DOCUMENT NUMBER: 136:20006
TITLE: Preparation of pyrrole derivatives as tyrosine phosphatase inhibitors for preventive and therapeutic drugs for diseases such as diabetes
INVENTOR(S): Matsumoto, Takahiro; Katayama, Nozomi; Mabuchi, Hiroshi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 337 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090067	**A1**	**20011129**	**WO 2001-JP4201**	**20010521**
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2410338	**AA**	**20011129**	**CA 2001-2410338**	**20010521**
AU 2001058784	**A5**	**20011203**	**AU 2001-58784**	**20010521**
JP 2002121186	**A2**	**20020423**	**JP 2001-150910**	**20010521**
EP 1284260	A1	20030219	EP 2001-932153	20010521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

US 2003144338	A1	20030731	US 2002-276674		20021115
US 6911468	B2	20050628			
PRIORITY APPLN. INFO.:			JP 2000-154441	A	20000522
			JP 2000-247954	A	20000810
			WO 2001-JP4201	W	20010521

OTHER SOURCE(S): MARPAT 136:20006
GI



I

AB Compds. of the general formula (I) or salts thereof [wherein X1 and X2 are each a free valency or a spacer having a C1-20 main chain; one of R1 and R2 is a cyclic group which bears a substituent selected from among (1) carboxylated C1-6 alkoxy groups which may be substituted and (2) carboxylated C1-6 aliph. hydrocarbon groups which may be substituted and may further have other substituent, and the other is an optionally substituted cyclic group or hydrogen; and R3, R4 and R5 are each hydrogen or a substituent, or alternatively R4 together with R3 or R5 may form an optionally substituted ring, with the proviso that some compds. of the general formula I are excluded.] are prepd. These compds. are useful as preventive and therapeutic drugs for diabetes, impaired glucose tolerance (IGT), tumors, autoimmune diseases, immunodeficiency, allergies, bone diseases, infections, joint diseases, hyperlipidemia, diabetes complications, obesity, cachexia, fatty liver, hypertension, liver diseases, polycystic ovary syndromes, muscular dystrophy, myocardial infarction, angina pectoris, cerebral infarction, syndrome X, high-blood insulin, inflammation, and arteriosclerosis or as improvers for insulin resistance or enhancers for insulin sensitivity or blood platelet aggregation inhibitors. Thus, cyclocondensation of 4-octylphenylamine with 1-(4-benzyloxyphenyl)-1,4-pentanedione in the presence of p-MeC6H4SO3H.H2O in PhMe under reflux for 12 h and hydrogenation of the resulting 1-(4-pentylphenyl)-2-methyl-5-(4-benzyloxyphenyl)-1H-pyrrole over 10% Pd-C in ethanol under hydrogen atm. gave 4-[1-(4-pentylphenyl)-5-methyl-1H-pyrrol-2-yl]phenol which underwent Mitsunobu reaction with (S)-2-hydroxy-3-phenylpropanoic acid Et ester using 1,1'-(azocarbonyl)dipiperidine and Ph3P in PhMe at 80? for 12 h to give (2R)-2-{[4-[1-(4-pentylphenyl)-5-methyl-1H-pyrrol-2-yl]phenyl]oxy}-3-phenylpropanoic acid Et ester. The latter ester was converted into (2R)-2-{[4-[1-(4-pentylphenyl)-5-methyl-1H-pyrrol-2-yl]phenyl]oxy}-3-phenylpropanoic acid sodium salt (II). II showed IC50 of 0.09 μM against human protein tyrosine phosphatase-1B. Tablet formulations contg. specific I, e.g. (2R)-2-{4-[1-[2-(4-bromophenyl)ethan-1-yl]-5-methyl-1H-pyrrol-2-yl]phenoxy}-3-phenylpropanoic acid, were described.

IT **376635-68-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrole derivs. as tyrosine phosphatase inhibitors for

preventive and therapeutic drugs for diseases such as diabetes)

RN 376635-68-6 HCAPLUS

CN Benzenepropanoic acid, α-[4-[2-[2-(2-[1,1'-biphenyl]-2-ylethyl)-5-methyl-1H-pyrrol-1-yl]ethyl]phenoxy]-, sodium salt, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Cited References

ACCESSION NUMBER: 2001:713284 HCAPLUS
DOCUMENT NUMBER: 135:242458
TITLE: Preparation of amphipathic aldehyde glucuronides and their use as adjuvants and immunoeffectors
INVENTOR(S): Johnson, David
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070663	**A2**	**20010927**	**WO 2001-US8548**	**20010316**
WO 2001070663	A3	20020516		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2403553	**AA**	**20010927**	**CA 2001-2403553**	**20010316**
US 2001053363	**A1**	**20011220**	**US 2001-810915**	**20010316**
US 6649172	B2	20031118		
EP 1265840	A2	20021218	EP 2001-918784	20010316

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003528068	T2	20030924	JP 2001-568876		20010316
US 2004063647	A1	20040401	US 2003-652797		20030828
PRIORITY APPLN. INFO.:			US 2000-190466P	P	20000317
			US 2001-810915	A1	20010316
			WO 2001-US8548	W	20010316

OTHER SOURCE(S): MARPAT 135:242458

GI



AB This invention relates to the prepn. of arom. aldehyde contg. compds. I wherein R is H, CHO; R1 is H, alkyl, saccharyl, acyl, CO2H; R2 is H, alkyl, substituted alkyl, and their uses as adjuvants and immunoeffectors. Thus, 4-[(3-formyl-4-hydroxyyphenoxy)methyl]benzoic acid was prepd. and tested in mice for its adjuvant activity.

IT **360078-75-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amphipathic aldehyde glucuronides and their use as adjuvants and immunoeffectors)

RN 360078-75-7 HCAPLUS

CN Benzoic acid, 4-[[4-(carboxymethoxy)-3-formylphenoxy]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	2001:327444 HCAPLUS
DOCUMENT NUMBER:	135:132175
TITLE:	A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
AUTHOR(S):	Oliver, William R., Jr.; Shenk, Jennifer L.; Snaith, Mike R.; Russell, Caroline S.; Plunket, Kelli D.; Bodkin, Noni L.; Lewis, Michael C.; Winegar, Deborah A.; Sznaidman, Marcos L.; Lambert, Millard H.; Xu, H. Eric; Sternbach, Daniel D.; Kliewer, Steven A.; Hansen, Barbara C.; Willson, Timothy M.
CORPORATE SOURCE:	Metabolic Diseases Drug Discovery, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
SOURCE:	Proceedings of the National Academy of Sciences of the United States of America (**2001**), 98(9), 5306-5311

CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The peroxisome proliferator-activated receptors (PPARs) are dietary lipid sensors that regulate fatty acid and carbohydrate metab. The hypolipidemic effects of the fibrate drugs and the antidiabetic effects of the glitazone drugs in humans are due to activation of the α (NR1C1) and γ (NR1C3) subtypes, resp. By contrast, the therapeutic potential of the δ (NR1C2) subtype is unknown, due in part to the lack of selective ligands. We have used combinatorial chem. and structure-based drug design to develop a potent and subtype-selective PPARδ agonist, GW501516. In macrophages, fibroblasts, and intestinal cells, GW501516 increases expression of the reverse cholesterol transporter ATP-binding cassette A1 and induces apolipoprotein A1-specific cholesterol efflux. When dosed to insulin-resistant middle-aged obese rhesus monkeys, GW501516 causes a dramatic dose-dependent rise in serum high d. lipoprotein cholesterol while lowering the levels of small-dense low d. lipoprotein, fasting triglycerides, and fasting insulin. Our results suggest that PPARδ agonists may be effective drugs to increase reverse cholesterol transport and decrease cardiovascular disease assocd. with the metabolic syndrome X.

IT 317318-70-0, GW 501516
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(GW501516 promotes reverse cholesterol transport)

RN 317318-70-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:12437 HCAPLUS
DOCUMENT NUMBER: 134:86235
TITLE: Preparation of thiazoles and oxazoles as selective activators of human PPAR delta
INVENTOR(S): Chao, Esther Yu-Hsuan; Haffner, Curt Dale; Lambert, Millard Hurst, III; Maloney, Patrick Reed; Sierra, Michael Lawrence; Sternbach, Daniel David; Sznaidman, Marcos Luis; Willson, Timothy Mark; Xu, Huaqiang Eric;

	Gellibert, Francoise Jeanne
PATENT ASSIGNEE(S):	Glaxo Group Limited, UK; et al.
SOURCE:	PCT Int. Appl., 83 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000603	**A1**	**20010104**	**WO 2000-EP5720**	**20000622**
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2377126	**AA**	**20010104**	**CA 2000-2377126**	**20000622**
BR 2000011891	**A**	**20020305**	**BR 2000-11891**	**20000622**
EP 1189895	**A1**	**20020327**	**EP 2000-943847**	**20000622**
EP 1189895	B1	20050608		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103612	**T2**	**20020521**	**TR 2001-200103612**	**20000622**
JP 2003503399	T2	20030128	JP 2001-507012	20000622
JP 3490704	B2	20040126		
AU 765347	B2	20030918	AU 2000-58171	20000622
JP 2003313141	A2	20031106	JP 2003-98492	20000622
NZ 515676	A	20040528	NZ 2000-515676	20000622
AT 297384	E	20050615	AT 2000-943847	20000622
ZA 2001009804	A	20030228	ZA 2001-9804	20011128
NO 2001006078	**A**	**20011213**	**NO 2001-6078**	**20011213**
US 6710063	B1	20040323	US 2001-18935	20011219
US 2003203947	A1	20031030	US 2003-383011	20030306
US 6723740	B2	20040420		

PRIORITY APPLN. INFO.:	GB 1999-14977	A	19990625
	JP 2001-507012	A3	20000622
	WO 2000-EP5720	W	20000622
	US 2001-18935	A1	20011219

OTHER SOURCE(S): MARPAT 134:86235
GI



AB The title compds. [I; X = CO2H (or its ester), tetrazole; X1 = NH, NMe, O, etc.; X2 = O, S; R1, R2 = H, Me, OMe, halo; n = 1-2; one of Y and Z = N and the other = S or O; y = 0-5; R3 = CF3, halo], useful as selective activators of human PPARδ, were prepd. E.g., a multi-step synthesis of the thiazole II was given. All of the exemplified acids I (X = CO2H) showed at least 50% activation hPPARδ relative to the pos. control at ? 10-7 M. Most of the exemplified acids I (X = CO2H) were at least 10-fold selective for hPPARδ over hPPARα and hPPARγ. One of the compds. I was studied in a Rhesus model and showed a shift in the LDLc compn. to fewer and larger LDLc particles.

IT **317318-16-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thiazoles and oxazoles as selective activators of human PPAR delta)

RN 317318-16-4 HCAPLUS

CN Acetic acid, [4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:421087 HCAPLUS

DOCUMENT NUMBER: 133:59090
TITLE: Preparation of phenylglycine derivatives as pharmaceuticals
INVENTOR(S): Ackermann, Jean; Alig, Leo; Chucholowski, Alexander; Groebke, Katrin; Hilpert, Kurt; Kuehne, Holger; Obst, Ulrike; Weber, Lutz; Wessel, Hans Peter
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035858	**A1**	**20000622**	**WO 1999-EP9520**	**19991206**
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2354023	**AA**	**20000622**	**CA 1999-2354023**	**19991206**
BR 9916111	**A**	**20010904**	**BR 1999-16111**	**19991206**
EP 1149069	**A1**	**20011031**	**EP 1999-962221**	**19991206**
EP 1149069	B1	20040825		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101744	**T2**	**20011221**	**TR 2001-200101744**	**19991206**
JP 2002532459	T2	20021002	JP 2000-588120	19991206
JP 3676236	B2	20050727		
RU 2198871	C1	20030220	RU 2001-119160	19991206
AU 758229	B2	20030320	AU 2000-18627	19991206
NZ 511927	A	20040227	NZ 1999-511927	19991206
AT 274491	E	20040915	AT 1999-962221	19991206
ES 2230909	T3	20050501	ES 1999-962221	19991206
US 6242644	**B1**	**20010605**	**US 1999-460901**	**19991214**
US 2001001799	**A1**	**20010524**	**US 2001-758977**	**20010112**
US 6476264	B2	20021105		
ZA 2001004034	A	20020819	ZA 2001-4034	20010517
HR 2001000427	**A1**	**20020630**	**HR 2001-427**	**20010606**
NO 2001002921	**A**	**20010614**	**NO 2001-2921**	**20010613**
US 2003083504	A1	20030501	US 2002-264943	20021004
US 6683215	B2	20040127		
US 2004034231	A1	20040219	US 2003-639030	20030812

PRIORITY APPLN. INFO.:

EP 1998-123721	A	19981214
WO 1999-EP9520	W	19991206
US 1999-460901	A1	19991214
US 2001-758977	A3	20010112
US 2002-264943	A3	20021004

OTHER SOURCE(S): MARPAT 133:59090
GI



AB Novel N-(4-carbamimidoylphenyl)glycine derivs. I [R1 is H or the residue of an ester group which is cleavable under physiol. conditions; E = H, OH; three of X1 to X4 independently represent (un)substituted carbon and the fourth represents (un)substituted carbon or N; one of G1 and G2 represents H and the other represents H, alkyl, hydroxy, alkoxy, aroyl, CO2R or O2CR, where R = (un)substituted alkyl] or their hydrates, solvates or physiol. usable salts were prepd. as pharmaceuticals, e.g., antithrombotics. Thus, (RS)-(4-benzyloxy-3-methoxyphenyl)(4-carbamimidoylphenylamino)acetic acid was prepd. and showed Ki = 0.061 μM/L for inhibition of the amidolytic activity of factor VIIa/tissue factor complex.

IT **277319-34-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylglycine derivs. as pharmaceuticals)

RN 277319-34-3 HCAPLUS

CN Benzeneacetic acid, α-[[4-(aminoiminomethyl)phenyl]amino]-2-(carboxymethoxy)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:335399 HCAPLUS
DOCUMENT NUMBER: 132:334458
TITLE: Preparation of 4-oxothiazole-5-acetamides as PPARγ receptor antagonists
INVENTOR(S): Collins, Jon Loren; Holmes, Christopher Patrick; Lenhard, James Martin; Willson, Timothy Mark
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027832	**A2**	**20000518**	**WO 1999-EP8477**	**19991109**
WO 2000027832	A3	20000727		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1129084	**A2**	**20010905**	**EP 1999-971805**	**19991109**
EP 1129084	B1	20050302		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529458	T2	20020910	JP 2000-581011	19991109
AT 289995	E	20050315	AT 1999-971805	19991109
US 6541492	B1	20030401	US 2001-831672	20010511
US 2002151569	A1	20021017	US 2002-115550	20020403
PRIORITY APPLN. INFO.:			GB 1998-24614	A 19981111
			WO 1999-EP8477	W 19991109
			US 2001-831672	A3 20010511

OTHER SOURCE(S): MARPAT 132:334458

GI



I

AB Title compds. [I; R = R4Z(CH2)n; R1 = hexyl, heptyl, alkylphenyl; R2 = Bu or (halo)benzyl; R3 = Bu or (un)substituted CH2Ph; R4 = CO2H, ureido, OH, OMe, etc.; Z = 1,4-phenylene; R4Z = 3,4-methylenedioxyphenyl; n = 2-4] were prepd. Thus, N-protected 4-(HO2C)C6H4(CH2)4NH2 was condensed with Sasrin resin and the deprotected product cyclocondensed with octanal and HO2CCH(SH)CH2CO2H to give, after amidation and resin cleavage, I [R = 4-(HO2C)C6H4(CH2)4, R1 = heptyl, R2 = R3 = CH2Ph]. Data for biol. activity of I were given.

IT **267413-00-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-oxothiazole-5-acetamides as PPARγ receptor antagonists)

RN 267413-00-3 HCAPLUS

CN Acetic acid, [4-[2-[(2R,5R)-5-[2-[bis(phenylmethyl)amino]-2-oxoethyl]-2-heptyl-4-oxo-3-thiazolidinyl]ethyl]phenoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 16 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:96030 HCAPLUS
DOCUMENT NUMBER: 130:139342
TITLE: Preparation of arylbenzimidazoles and analogs as interleukin 1β inhibitors
INVENTOR(S): De Nanteuil, Guillaume; Portevin, Bernard; Bonnet, Jacqueline; Fradin, Armel
PATENT ASSIGNEE(S): Adir et Compagnie, Fr.
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 894795	**A1**	**19990203**	**EP 1998-401920**	**19980728**
EP 894795	B1	20010606		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2766822	**A1**	**19990205**	**FR 1997-9710**	**19970730**
FR 2766822	B1	20010223		
US 6040327	**A**	**20000321**	**US 1998-120487**	**19980722**
JP 11100368	**A2**	**19990413**	**JP 1998-210640**	**19980727**
PT 894795	**T**	**20010928**	**PT 1998-401920**	**19980728**
ES 2159922	**T3**	**20011016**	**ES 1998-401920**	**19980728**
CA 2244438	**AA**	**19990130**	**CA 1998-2244438**	**19980729**
NO 9803493	**A**	**19990201**	**NO 1998-3493**	**19980729**
CN 1210859	**A**	**19990317**	**CN 1998-117575**	**19980729**
CN 1087740	B	20020717		
ZA 9806814	**A**	**19990202**	**ZA 1998-6814**	**19980730**
AU 9878608	**A1**	**19990211**	**AU 1998-78608**	**19980730**
AU 734447	B2	20010614		
BR 9802804	**A**	**20000502**	**BR 1998-2804**	**19980730**
HK 1018440	A1	20021101	HK 1999-103381	19990805

GR 3036473	T3	20011130	GR 2001-401332		20010830
PRIORITY APPLN. INFO.:			FR 1997-9710	A	19970730
OTHER SOURCE(S):	MARPAT 130:139342				

GI



AB Title compds. [I; R = CRaRbR1; R1 = halo, OH, alkoxy, arylmethyl, etc.; Ra,Rb = H, OH, (ar)alkyl; R2 = 1 or 2 (hetero)aryl; Z = O, S, (alkyl)imino] were prepd. Thus, 2-amino-4-chloronitrobenzene was aminated by imidazole and the reduced product cyclocondensed with PhOCH2CO2H to give title compd. II. Data for biol. activity of I were given.

IT 220067-56-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylbenzimidazoles and analogs as interleukin 1β inhibitors)

RN 220067-56-1 HCAPLUS

CN Acetic acid, [4-[[[5-(1H-imidazol-1-yl)-1H-benzimidazol-2-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	1998:324824 HCAPLUS
DOCUMENT NUMBER:	129:27961
TITLE:	Preparation of heterocyclyl-substituted piperazines for the prevention or treatment of a disease mediated by the binding of adhesion molecules to GPIIb/IIIa
INVENTOR(S):	Mills, Stuart Dennett
PATENT ASSIGNEE(S):	Zeneca Ltd., UK
SOURCE:	U.S., 68 pp., Cont.-in-part of U.S. 5,563,141. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5753659	A	19980519	US 1995-458180	19950602
US 5563141	A	19961008	US 1994-218174	19940328
US 5750754	A	19980512	US 1996-658097	19960604

PRIORITY APPLN. INFO.:

GB 1993-6451	A	19930329
GB 1993-25610	A	19931215
US 1994-218174	A2	19940328
GB 1993-6453	A	19930329
GB 1993-25605	A	19931215
GB 1995-18188	A	19950907

AB The title compds. [(M1)n-Q-(M2)1-n-L-A; n = 0-1; M1 = NH2; Q = an arom. heterocyclic group contg. N atom; M2 = imino; L = template; A = an acidic group, or its ester or amide, or sulfonamide] and their pharmaceutically acceptable salts and pro-drugs, useful for the prevention or treatment of a disease mediated by the binding of adhesion mols. to GPIIb/IIIa, for the inhibition of platelet aggregation, and for the treatment of unstable angina. Thus, reaction of Me 4-bromoacetylphenoxyacetate with 1-(4-pyridyl)piperazine in MeCN afforded Me 4-{2-[4-(4-pyridyl)piperazin-1-yl]acetyl}phenoxyacetate which showed pIC50 of 5.8-6.4 against binding of fibrinogen to GPIIb/IIIa.

IT **166951-67-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyl-substituted piperazines for the prevention or treatment of a disease mediated by the binding of adhesion mols. to GPIIb/IIIa)

RN 166951-67-3 HCAPLUS

CN Acetic acid, [4-[2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing Ref. Avail.

ACCESSION NUMBER: 1998:55525 HCAPLUS
DOCUMENT NUMBER: 128:128032
TITLE: Preparation of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists
INVENTOR(S): Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 270 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9800134	**A1**	**19980108**	**WO 1997-US11133**	**19970625**
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2258093	**AA**	**19980108**	**CA 1997-2258093**	**19970625**
AU 9735798	**A1**	**19980121**	**AU 1997-35798**	**19970625**
AU 721130	B2	20000622		
EP 912175	**A1**	**19990506**	**EP 1997-932307**	**19970625**
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000514061	**T2**	**20001024**	**JP 1998-504291**	**19970625**

PRIORITY APPLN. INFO.:

US 1996-20975P	P	19960628
GB 1997-893	A	19970117
WO 1997-US11133	W	19970625

OTHER SOURCE(S): MARPAT 128:128032
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. X-Y-Z-A-B [I; X = (un)substituted 5-7- membered arom. or nonarom. ring, having 1-3 heteroatoms selected from N, O, and S, (un)substituted 9-10 membered fused arom. or nonarom. ring, having 1-3 heteroatoms selected from N, O, and S; Y = (un)substituted 5-6 membered arom. or nonarom. ring, having 0-3 heteroatoms selected from N, O, and S; XY = II, III, IV, V; Z = C(O)NR4, N(R4)C(O), CH2CH2, CH:CH, etc.; R4 = H, C1-4 alkyl, C3-6 cycloalkyl; A = (un)substituted 5-6 membered arom. ring, having 0-3 heteroatoms selected from N, O, and S, 9-10 membered fused arom. ring having 0-3 heteroatoms (N, O, and S); B = C(CH2)mCO2R9, (CH2)nCO2R9, CH(R8)(CH2)pCO2R9, OCH(R8)(CH2)pCO2R9 (wherein m = 1-3; n = 0-3; p = 0-3; R8 = H, aryl, amino, etc.; R9 = H, aryl, C1-8 alkyl, etc.)], useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus or embolus formation, inhibiting osteoclast mediated bone resorption, inhibiting angiogenesis, and in inhibiting tumor growth, were prepd. and formulated. Thus, a few-step detailed synthesis of the acid VI which showed IC50 in the range between 10 nM and 50 mM against ADP-stimulated platelet aggregation, was described.

IT **201808-81-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists)

RN 201808-81-3 HCAPLUS
CN Acetic acid, [4-[2-[4-(1-piperazinyl)phenyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:631661 HCAPLUS
DOCUMENT NUMBER: 127:242815
TITLE: Anionic- and Lipophilic-Mediated Surface Binding Inhibitors of Human Leukocyte Elastase
AUTHOR(S): Regan, John; McGarry, Daniel; Bruno, Joseph; Green, Daniel; Newman, Jack; Hsu, Chin-Yi; Kline, Jane; Barton, Jeffrey; Travis, Jeffrey; Choi, Yong Mi; Volz, Francis; Pauls, Henry; Harrison, Richard; Zilberstein, Asher; Ben-Sasson, Shmuel A.; Chang, Michael
CORPORATE SOURCE: Departments of Medicinal Chemistry and Inflammation Biology, Rhone-Poulenc Rorer, Collegeville, PA, 19426, USA
SOURCE: Journal of Medicinal Chemistry (**1997**), 40(21), 3408-3422
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We report the synthesis of a series of diphenylmethane-based oligomers contg. anionic and lipophilic functionalities that are potent inhibitors of human leukocyte elastase (HLE). The enzyme inhibition is regulated by the size of the oligomer, as well as, the no. of charges. Lipophilicity is an important element in detg. potency and specificity against other basic enzymes. Compds. whose scaffolds contain three phenoxyacetic acid groups and three alkyl ethers are competitive and specific inhibitors of HLE with Ki = 20 nM. The mechanism of action of this class of compds. is believed to involve multidendate interactions with the surface of HLE near the active site which prevents substrate access to the catalytic site.

IT **147067-39-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of diphenylmethane-based oligomers as selective inhibitors of human leukocyte elastase)

RN 147067-39-8 HCAPLUS
CN Acetic acid, [2-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:513484 HCAPLUS
DOCUMENT NUMBER: 127:190753
TITLE: Preparation of heterocyclic derivatives as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa
INVENTOR(S): Wayne, Michael Garth; Smithers, Michael James; Rayner, John Wall; Faull, Alan Wellington; Pearce, Robert James; Brewster, Andrew George; Shute, Richard Eden; Mills, Stuart Dennett; Caulkett, Peter William Rodney
PATENT ASSIGNEE(S): Zeneca Ltd., UK
SOURCE: U.S., 42 pp., Cont.-in-part of U.S. 5,556,977.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5652242	A	19970729	US 1995-457538	19950601
US 5556977	A	19960917	US 1994-218171	19940328
EP 825184	A1	19980225	EP 1997-117909	19940328
EP 825184	B1	20010620		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
CA 2194397	AA	19961205	CA 1996-2194397	19960528
WO 9638416	A1	19961205	WO 1996-GB1260	19960528
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
AU 9658272	A1	19961218	AU 1996-58272	19960528
AU 710105	B2	19990916		
GB 2304340	A1	19970319	GB 1996-27127	19960528
GB 2304340	B2	19980729		
EP 796247	A1	19970924	EP 1996-919906	19960528
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

BR 9606409	A	19970930	BR 1996-6409		19960528
DE 19680509	T	19971204	DE 1996-19680509		19960528
JP 09512836	T2	19971222	JP 1996-536281		19960528
JP 2885941	B2	19990426			
AT 9609005	A	19991215	AT 1996-9005		19960528
AT 406675	B	20000725			
ES 2137886	A1	19991216	ES 1997-50006		19960528
ES 2137886	B1	20000816			
CH 691808	A	20011031	CH 1997-224		19960528
ZA 9604509	A	19961202	ZA 1996-4509		19960531
NL 1003243	C2	19961204	NL 1996-1003243		19960531
FR 2734818	A1	19961206	FR 1996-6747		19960531
FR 2734818	B1	19980710			
BE 1009520	A5	19970401	BE 1996-491		19960531
US 5750754	A	19980512	US 1996-658097		19960604
SE 9700203	A	19970124	SE 1997-203		19970124
SE 510812	C2	19990628			
FI 9700393	A	19970130	FI 1997-393		19970130
DK 9700106	A	19970401	DK 1997-106		19970130
NO 9700437	A	19970220	NO 1997-437		19970131
NO 307460	B1	20000410			
US 5728701	A	19980317	US 1997-820003		19970318
GR 3036640	T3	20011231	GR 2001-401498		20010918
PRIORITY APPLN. INFO.:			GB 1993-6453	A	19930329
			GB 1993-25605	A	19931215
			US 1994-218171	A2	19940328
			GB 1993-6451	A	19930329
			GB 1993-25610	A	19931215
			EP 1994-910494	A3	19940328
			US 1995-457538	A	19950601
			GB 1995-18188	A	19950907
			WO 1996-GB1260	W	19960528

OTHER SOURCE(S): MARPAT 127:190753
GI



AB The title compds. [I; M2 = NR3 (wherein R3 = H, C1-4 alkyl), etc.; X1 = a bond, C1-4 alkylene, C2-4 alkylene, etc.; Z1, Z1a = H, OH, halo, etc.; X2 = a bond, C1-4 alkylene, C2-4 alkylene, etc.; A1 = COOH, a metabolically stable ester, amide; R13 = H, C1-4 alkyl, C1-4 alkoxy, halo] and their pharmaceutically acceptable salts, useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa, were prepd. and formulated. Thus, reaction of Me 4-bromoacetylphenoxyacetate with 1-(4-pyridyl)piperazine in MeCN afforded the title compd. II which showed pIC50 of 7.2 against platelet aggregation.

IT 166951-67-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic derivs. as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa)

RN 166951-67-3 HCAPLUS
CN Acetic acid, [4-[2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:446484 HCAPLUS
DOCUMENT NUMBER: 127:171078
TITLE: Selective endothelin A receptor ligands. 1. Discovery and structure-activity of 2,4-disubstituted benzoic acid derivatives
AUTHOR(S): Astles, P. C.; Brown, T. J.; Handscombe, C. M.; Harper, M. F.; Harris, N. V.; Lewis, R. A.; Lockey, P. M.; McCarthy, C.; McLay, I. M.; Porter, B.; Roach, A. G.; Smith, C.; Walsh, R. J. A.
CORPORATE SOURCE: Rhone Poulenc Rorer, Dagenham Research Centre, Dagenham, RM10 7XS, UK
SOURCE: European Journal of Medicinal Chemistry (**1997**), 32(5), 409-423
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB This paper describes the discovery of a new non-peptide endothelin A (ETA) selective ligand, 2,4-dibenzyloxybenzoic acid (I), which inhibits the binding of [125I]ET-1 to ETA receptors with an IC50 of 9 μM (ET-1 = endothelin-1). Optimization of I resulted in compd. II which had an IC50 of 1 μM. One of the analogs of I, compd. III, was examd. in a functional assay and shown to antagonize ET-1-induced contraction of rat aorta. The identification of I was made through the application of ChemDBS-3D searching of our corporate database. The 3D query, using an arom. ring to a carboxylic acid group sepd. by 10.2 ? 1.1 Å, was derived from an examn. of common pharmacophoric distances found in the low energy conformations of two known ETA antagonists, the cyclic pentapeptide BQ 123 and myriceron caffeoyl ester.

IT **170281-54-6P**
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(benzoic acid deriv. endothelin A receptor ligand prepn. and structure-activity relationships)

RN 170281-54-6 HCAPLUS

CN Acetic acid, [2,4-bis(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:400093 HCAPLUS
DOCUMENT NUMBER: 127:17681
TITLE: Five-membered heterocycles [thiazoles, imidazoles, and thiadiazoles], pharmaceutical agents containing them, their use as aggregation inhibitors, and methods for their production
INVENTOR(S): Linz, Guenter; Himmelsbach, Frank; Pieper, Helmut; Austel, Volkhard; Guth, Brian; Weisenberger, Johannes
PATENT ASSIGNEE(S): Dr. Karl Thomae Gmbh, Germany
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9715567	A1	19970501	WO 1996-EP4390	19961010
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19539091	A1	19970424	DE 1995-19539091	19951020
DE 19548798	A1	19970703	DE 1995-19548798	19951227
EP 858457	A1	19980819	EP 1996-934603	19961010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11513382	T2	19991116	JP 1996-513786	19961010

PRIORITY APPLN. INFO.:

DE 1995-19539091	A	19951020
DE 1995-19548798	A	19951227
WO 1996-EP4390	W	19961010

OTHER SOURCE(S): MARPAT 127:17681
GI



I

AB Disclosed are certain five-membered heterocycles, their tautomers, stereoisomers, mixts., and salts, having valuable pharmacol. properties, esp. cellular aggregation-inhibiting properties. Also disclosed are pharmaceutical agents contg. the compds., their use, and methods of producing them. The compds. have antiinflammatory, osteoporosis-inhibiting, antithrombotic, antiaggregatory, and tumor- and metastasis-inhibiting properties. Prepns. of approx. 100 invention compds. and 60 intermediates are described, and six std. pharmaceutical formulations are given. The example compd. I.HBr had an EC50 of 0.13 μM for inhibition of collagen-induced platelet aggregation in vitro.

IT 190515-14-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of five-membered heterocycles as aggregation inhibitors)
RN 190515-14-1 HCAPLUS
CN Acetic acid, [4-[[5-(4-piperidinyl)-1,3,4-thiadiazol-2-yl]methoxy]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 23 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:97157 HCAPLUS
DOCUMENT NUMBER: 126:157280
TITLE: Preparation of aromatic alkanoic acid and alkanol derivatives as antithrombotics
INVENTOR(S): Hashizume, Hiroichi; Hagiwara, Masaki; Myamae, Tetsuhisa; Ogawa, Masaji; Ppongo, Tomoko; Morikawa, Tadanori
PATENT ASSIGNEE(S): Fuji Yakuhin Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08333287	**A2**	**19961217**	**JP 1995-158813**	**19950602**
PRIORITY APPLN. INFO.:			JP 1995-158813	19950602

OTHER SOURCE(S): MARPAT 126:157280
GI



AB The title compds. I [A = (un)substituted benzene, etc.; X, Y = (O- or N-contg.) alkylene; Z = amino, OH, carboxyl, aminocarbonyl, etc.] are prepd. The title compds. in vitro showed IC50 values of 0.068 to 15.3 μM against thrombin-induced platelet aggregation.

IT **185995-32-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arom. alkanoic acid and alkanol derivs. as antithrombotics)

RN 185995-32-8 HCAPLUS
CN Acetic acid, [4-(2-[1,1':2',1''-terphenyl]-4'-ylethyl)phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 24 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:15490 HCAPLUS
DOCUMENT NUMBER: 126:60367
TITLE: Preparation of aryloxy- and arylthioglutamic acids as excitatory amino acid receptor antagonists
INVENTOR(S): Heinz, Lawrence J.; Lunn, William H. W.; Schoepp, Darryle D.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 161,830, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5576323	**A**	**19961119**	**US 1994-322632**	**19941013**
ZA 9409405	**A**	**19960528**	**ZA 1994-9405**	**19941128**
CA 2136904	**AA**	**19950604**	**CA 1994-2136904**	**19941129**
NO 9404578	**A**	**19950606**	**NO 1994-4578**	**19941129**
AU 9479151	**A1**	**19950608**	**AU 1994-79151**	**19941130**
AU 676781	B2	19970320		
BR 9404809	**A**	**19950801**	**BR 1994-4809**	**19941201**
FI 9405704	**A**	**19950604**	**FI 1994-5704**	**19941202**
EP 658539	**A1**	**19950621**	**EP 1994-308949**	**19941202**
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
HU 69181	**A2**	**19950828**	**HU 1994-3469**	**19941202**
CN 1108240	**A**	**19950913**	**CN 1994-119360**	**19941202**
JP 07267908	**A2**	**19951017**	**JP 1994-299390**	**19941202**
US 5843997	**A**	**19981201**	**US 1996-626447**	**19960402**

PRIORITY APPLN. INFO.: US 1993-161830 B2 19931203
US 1994-322632 A 19941013

OTHER SOURCE(S): MARPAT 126:60367

AB Novel compds. R3pX3mX2sX1nCH(CO2R2)(CH2)rCH(NH2)CO2R1 [R1, R2 = H, protective group, R3, X2 = (un)substituted aryl or heterocyclyl group, X1 = NH2 or substituted amino, O, S, X3 = alkylene, alkenediyl, oxoalkylene, oxyalkylene, etc., m, n, s = 0, 1, p = 0-3, q = 0-6, r = 1, 2] or their pharmaceutically acceptable salts were prepd. as antagonists of excitatory amino acid receptors. Thus, Me 3-hydroxy-2-pyrrolidone-5-carboxylate was prepd. in 4 steps from cyclopentadiene and benzyl N-hydroxycarbamate and etherified with phenol and treated with LiOH in H2O-THF to afford 4-phenoxyglutamic acid. The latter at 10 μM concn. gave 88.0% displacement of 3H-glutamate binding from rat brain cell membranes. Formulation contg. the title compds. are given.

IT **170012-28-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryloxy- and arylthioglutamic acids as excitatory amino acid

receptor antagonists)
RN 170012-28-9 HCAPLUS
CN Glutamic acid, 4-[4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 25 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1996:531795 HCAPLUS
DOCUMENT NUMBER: 125:195688
TITLE: Preparation of 1-(piperazinocarbonyl)piperidine-4-alkanoates and analogs as cell aggregation inhibitors
INVENTOR(S): Pieper, Helmut; Austel, Volkhard; Himmelsbach, Frank; Linz, Guenter; Guth, Brian; Weisenberger, Johannes
PATENT ASSIGNEE(S): Dr. Karl Thomae Gmbh, Germany
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620173	A1	19960704	WO 1995-EP5031	19951219
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 4446301	A1	19960627	DE 1994-4446301	19941223
DE 19526678	A1	19970123	DE 1995-19526678	19950721
DE 19533639	A1	19970313	DE 1995-19533639	19950912
AU 9644324	A1	19960719	AU 1996-44324	19951219
EP 799202	A1	19971008	EP 1995-943168	19951219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
BR 9510360	A	19971223	BR 1995-10360	19951219
JP 10511374	T2	19981104	JP 1995-520188	19951219
ZA 9510956	A	19970623	ZA 1995-10956	19951227
FI 9702646	A	19970819	FI 1997-2646	19970619
NO 9702881	A	19970620	NO 1997-2881	19970620

PRIORITY APPLN. INFO.:

DE 1994-4446301	A	19941223
DE 1995-19526678	A	19950721
DE 1995-19533639	A	19950912
WO 1995-EP5031	W	19951219

OTHER SOURCE(S): MARPAT 125:195688
GI



AB R1ZZ1Z2Z3R2 [R1 = 3-pyrrolidinyl, 3- or 4-piperidinyl, 3- or 4-hexahydroazepinyl, etc.; R2 = OH, alkoxy, etc.; Z = (un)substituted piperazine-1,4-diyl; Z1 = CO, alkylene(carbonyl), carbonylalkyleneoxy, etc.; Z2 = cyclohexylnen, phenylene, heterocyclylene, etc.; Z3 = (alkylene)carbonyl, CH2CH(NH2)CO, carbonyliminoalkylenecarbonyl, etc.] were prepd. Thus, title compd. I.3HCl had IC50 of 0.012 and 0.094μM against BIBU 52 binding to, and collagen-induced aggregation of, platelets in vitro.

IT **180530-69-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-(piperazinocarbonyl)piperidine-4-alkanoates and analogs as cell aggregation inhibitors)

RN 180530-69-2 HCAPLUS

CN Acetic acid, [4-[2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]phenoxy]-, trihydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 26 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1996:464318 HCAPLUS
DOCUMENT NUMBER: 125:114673
TITLE: Preparation of benzyloxyphenylalkylbenzoates and related compounds as analgesics and prostaglandin antagonists
INVENTOR(S): Breault, Gloria Ann; Oldfield, John; Tucker, Howard; Warner, Peter
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9611902		A1	19960425	WO 1995-GB2417	19951012
W:	AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9508622		A	19960412	ZA 1995-8622	19951012
AU 9536162		A1	19960506	AU 1995-36162	19951012
EP 733033		A1	19960925	EP 1995-933542	19951012
EP 733033		B1	19991222		
R:	CH, DE, FR, GB, IT, LI				
JP 09511529		T2	19971118	JP 1995-513027	19951012
US 5811459		A	19980922	US 1996-647977	19960604
PRIORITY APPLN. INFO.:				GB 1994-20557 A	19941012
				WO 1995-GB2417 W	19951012

OTHER SOURCE(S): MARPAT 125:114673

AB Ortho-substituted Ph, naphthyl, and heterocyclic ethers (> 600 compds.) were prepd. for use in treating pain mediated by the E-type prostaglandins (no data). Thus, 2-PhCH2OC6H4(CH2)3C6H4CO2H-4 was prepd. from 2-HOC6H4Ac and 4-OCHC6H4CO2Me in 5 steps.

IT **179252-70-1P**

RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzyloxyphenylalkylbenzoates and related compds. as analgesics and prostaglandin antagonists)

RN 179252-70-1 HCAPLUS

CN Benzoic acid, 4-[3-[5-(carboxymethoxy)-2-(phenylmethoxy)phenyl]propyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 27 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:994147 HCAPLUS
DOCUMENT NUMBER: 124:55567
TITLE: Preparation of substituted benzene-derivative endothelin inhibitors
INVENTOR(S): Astles, Peter Charles; Harper, Mark Francis; Harris, Neil Victor; McLay, Ian McFarlane; Walsh, Roger John Aitchison; Lewis, Richard Alan; Smith, Christopher; Porter, Barry; McCarthy, Clive
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Ltd., UK
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9513262	A1	19950518	WO 1994-GB2499	19941114
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2176363	AA	19950518	CA 1994-2176363	19941114
AU 9481498	A1	19950529	AU 1994-81498	19941114
ZA 9409035	A	19960514	ZA 1994-9035	19941114
EP 728128	A1	19960828	EP 1995-900842	19941114
EP 728128	B1	19980916		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09505043	T2	19970520	JP 1995-513704	19941114
AT 171158	E	19981015	AT 1995-900842	19941114
ES 2123941	T3	19990116	ES 1995-900842	19941114
US 6211234	B1	20010403	US 1997-640922	19970627

PRIORITY APPLN. INFO.:	GB 1993-23382	A	19931112
	GB 1994-3363	A	19940222
	GB 1994-10750	A	19940527
	WO 1994-GB2499	W	19941114

OTHER SOURCE(S): MARPAT 124:55567
GI



I

AB The title compds. [I; R1 = H, (un)substituted hydroxyalkyl, carboxyalkyl, CN, NO2, (un)substituted alkoxy, etc.; R2 = arylalkoxy, heteroarylalkoxy, arylalkylthio, etc.; R3 = HO, alkoxy, aryloxy, etc.; R4 = (un)substituted alkyl or alkenyl; R5 = alkyl, alkenyl, halogen; m-p = 0, 1], useful as endothelin inhibitors (no data) for the treatment of diseases modulated by inhibiting endothelin (no data), are prepd. Thus, Me 2-benzyloxy-4-(4-chlorobenzyloxyl)benzoate was sapond., producing 2-benzyloxy-4-(4-chlorobenzyloxy)benzoic acid, m.p. 150-152?, in 44% yield.

IT 170281-54-6P
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted benzene endothelin inhibitors)

RN 170281-54-6 HCAPLUS

CN Acetic acid, [2,4-bis(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 28 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:905329 HCAPLUS
DOCUMENT NUMBER: 123:314527
TITLE: Preparation of aryloxyglutamates and related compounds as excitatory amino acid receptor antagonists.
INVENTOR(S): Heinz, Lawrence J.; Lunn, William Henry Walker; Schoepp, Darryle Darwin
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 52 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 658539	**A1**	**19950621**	**EP 1994-308949**	**19941202**
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5576323	**A**	**19961119**	**US 1994-322632**	**19941013**
PRIORITY APPLN. INFO.:			US 1993-161830	A 19931203
			US 1994-322632	A 19941013

OTHER SOURCE(S): CASREACT 123:314527; MARPAT 123:314527

AB H2NCH(CO2R3)(CH2)rCH(CO2R4)Zn(R1)sWm(R2)p [Z = NR5, O, S; W = CH3-p, (CH2)q, CH:CHCO, (CH2)qO, NR5, O, S, SO, SO2, etc.; m, n, s = 0, 1; p = 0-3; q = 0-6; r = 1, 2; m + n + p + s ?1; R1, R2 = (substituted) aryl, heterocyclyl; R3, R4 = H, protecting group; R5 = H, alkyl, acyl, alkylsulfonyl; with provisos], were prepd. Thus, Me 3-hydroxy-2-pyrrolidone-5-carboxylate (prepn. given) was treated with Ph3P, 2-naphthalenethiol, and di-Et azodicarboxylate in THF at 0? to give Me 3-(2-naphthalenethio)-2-pyrrolidone-5-carboxylate. The latter was treated with LiOH in THF/H2O to give 3-(2-naphthalenethio)glutamic acid. This at 100 μM gave 100.6% displacement of [3H]-Glu from crude rat forebrain membrane prepns.

IT **170012-28-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryloxyglutamates and related compds. as excitatory amino acid receptor antagonists)

RN 170012-28-9 HCAPLUS
CN Glutamic acid, 4-[4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 29 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:810381 HCAPLUS
DOCUMENT NUMBER: 123:227994
TITLE: Heterocyclic derivatives as platelet aggregation inhibitors

INVENTOR(S): Wayne, Michael Garth; Smithers, Michael James; Rayner, John Wall; Faull, Alan Wellington; Pearce, Robert James; Brewster, Andrew George; Shute, Richard Eden; Mills, Stuart Dennett; Caulkett, Peter William Rodney
PATENT ASSIGNEE(S): Zeneca Ltd., UK
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422834	**A1**	**19941013**	**WO 1994-GB647**	**19940328**
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2156070	**AA**	**19941013**	**CA 1994-2156070**	**19940328**
AU 9462889	**A1**	**19941024**	**AU 1994-62889**	**19940328**
AU 692438	B2	19980611		
EP 691959	**A1**	**19960117**	**EP 1994-910494**	**19940328**
EP 691959	B1	19980722		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9406613	**A**	**19960206**	**BR 1994-6613**	**19940328**
HU 72088	**A2**	**19960328**	**HU 1995-2290**	**19940328**
CN 1120334	**A**	**19960410**	**CN 1994-191664**	**19940328**
JP 08508291	**T2**	**19960903**	**JP 1994-521810**	**19940328**
EP 825184	**A1**	**19980225**	**EP 1997-117909**	**19940328**
EP 825184	B1	20010620		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 168678	**E**	**19980815**	**AT 1994-910494**	**19940328**
ES 2119184	**T3**	**19981001**	**ES 1994-910494**	**19940328**
RU 2142944	**C1**	**19991220**	**RU 1995-122602**	**19940328**
IL 109144	**A1**	**20000229**	**IL 1994-109144**	**19940328**
AT 202345	**E**	**20010715**	**AT 1997-117909**	**19940328**
ES 2159798	**T3**	**20011016**	**ES 1997-117909**	**19940328**
PT 825184	**T**	**20011130**	**PT 1997-117909**	**19940328**
FI 9504616	**A**	**19950928**	**FI 1995-4616**	**19950928**
NO 9503837	**A**	**19950928**	**NO 1995-3837**	**19950928**
US 5750754	**A**	**19980512**	**US 1996-658097**	**19960604**
GR 3036640	**T3**	**20011231**	**GR 2001-401498**	**20010918**

PRIORITY APPLN. INFO.:

GB 1993-6453	A	19930329
GB 1993-25605	A	19931215
GB 1993-6451	A	19930329
GB 1993-25610	A	19931215
EP 1994-910494	A3	19940328
WO 1994-GB647	W	19940328
GB 1995-18188	A	19950907

OTHER SOURCE(S): MARPAT 123:227994
GI



I

AB Pyridine derivs. and metabolically labile esters and amides thereof were disclosed as pharmaceuticals. The compds. are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. A specifically claimed compd. is 4-[2-[4-(4-pyridinyl)-1-piperazinyl]acetyl]phenoxyacetic acid (I).

IT **166951-67-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridine compds. platelet aggregation inhibitors)

RN 166951-67-3 HCAPLUS

CN Acetic acid, [4-[2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 30 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:758624 HCAPLUS
DOCUMENT NUMBER: 123:169654
TITLE: Preparation of heterocyclic compounds as platelet aggregation inhibitors
INVENTOR(S): Wayne, Michael Garth; Smithers, Michael James; Rayner, John Wall; Faull, Alan Wellington; Pearce, Robert James; Brewster, Andrew George; Shute, Richard Eden; Mills, Stuart Dennett; Caulkett, Peter William Rodney
PATENT ASSIGNEE(S): Zeneca Ltd., UK
SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422835	**A2**	**19941013**	**WO 1994-GB648**	**19940328**
WO 9422835	A3	19941222		

W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,

BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2155307	AA	19941013	CA 1994-2155307	19940328
AU 9462890	A1	19941024	AU 1994-62890	19940328
AU 692439	B2	19980611		
EP 690847	A1	19960110	EP 1994-910495	19940328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08509967	T2	19961022	JP 1994-521811	19940328
JP 3088016	B2	20000918		
US 5750754	A	19980512	US 1996-658097	19960604

PRIORITY APPLN. INFO.:

GB 1993-6451	A	19930329
GB 1993-25610	A	19931215
GB 1993-6453	A	19930329
GB 1993-25605	A	19931215
WO 1994-GB648	W	19940328
GB 1995-18188	A	19950907

OTHER SOURCE(S): MARPAT 123:169654

GI



I

AB Title compds. [I; (M1)nQ(M2)1-nLA wherein = 0, 1; M1 = amino; Q = N-heterocyclyl; M2 = imino; L = template; A = an acidic group, or ester, amide deriv., sulfonamide] and pharmaceutically acceptable salts and pro-drugs thereof are prepd. Me 4-(bromoacetyl)phenoxyacetate in MeCN was added to 1-(4-pyridyl)piperazine in MeCN to give the title compd II. Platelet aggregation inhibition was demonstrated by I. Pharmaceutical formulations comprising I are given.

IT 166951-67-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic compds. as platelet aggregation inhibitors)

RN 166951-67-3 HCAPLUS

CN Acetic acid, [4-[2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 31 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1993:6872 HCAPLUS
DOCUMENT NUMBER: 118:6872
TITLE: Preparation of N-(3-pyridylalkyl)sulfonamide derivatives as drugs
INVENTOR(S): Ohnishi, Hiroyuki; Miyakoshi, Masazumi; Isozaki, Masashi; Fujitake, Masayuki; Mikami, Naoya; Yanoshita, Ryohei; Akasofu, Harue; Sugizaki, Katsuyoshi; Nakata, Nobuyuki
PATENT ASSIGNEE(S): Terumo Corp., Japan
SOURCE: Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 501876	A1	19920902	EP 1992-400487	19920225
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
JP 04270265	A2	19920925	JP 1991-114154	19910225
JP 05043546	A2	19930223	JP 1991-200650	19910809
JP 05043547	A2	19930223	JP 1991-200651	19910809
US 5374641	A	19941220	US 1992-840165	19920224
PRIORITY APPLN. INFO.:			JP 1991-114154 A	19910225
			JP 1991-200650 A	19910809
			JP 1991-200651 A	19910809

OTHER SOURCE(S): MARPAT 118:6872
GI



AB Title compds. I [X = H, HO, halo, O2N, cyano, alkyl, alkoxy; R = R1O, R2O2C(CH2)aO, R3O2CO, R6O2C(R5)C:C(R4), R7O2C(CH2)b wherein R1-R7 = H, alkyl; a, b 0-4; Q = 1,4-phenylene, certain divalent heterocyclyl; Z = H, alkyl, alkoxycarbonyl, PhCH2O2C, OCH; l, m, n = 0-4] or salts thereof, useful as TxA2 prodn. inhibitors, TxA2 antagonists, prostaglandin H2 antagonists, and antithrombotic and antiallergic agents, are prepd. NCCH2P(O)(OEt)2 was added to a NaOEt-EtOH soln. followed by 4-(methoxymethoxyphenyl) 3-pyridyl ketone to give (E)- and (Z)-3-(4-methoxymethoxyphenyl)-3-(3-pyridyl)acrylonitrile, which were reduced with NaBH4 to the propionitrile; this in MePh was treated with (Me2CHCH2)AlH to give the aldehyde, to which was added Jones reagent to give the propionic acid. The latter in C6H6 was treated with N3P(O)(OPh)2 and Et3N, refluxed and treated with PhCH2OH to give the corresponding amine benzyl carbamate, to which in THF was added n-BuLi and 4-ClC6H4SO2Cl to give the sulfonamide; this in 3 steps was converted to the title compd. I (X = 4-Cl, Z = H, l = n = 0, m = 1, Q = 1,4-C6H4, R = EtO2CCH2O) (II).

In a test for TxA2 synthesis inhibition in human platelets, the IC50 of II was 3.3 8-10 ıM.

IT **144824-29-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as drug)

RN 144824-29-3 HCAPLUS

CN Acetic acid, [4-[2-[[(4-methylphenyl)sulfonyl]amino]-2-(3-pyridinyl)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 32 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1992:531082 HCAPLUS
DOCUMENT NUMBER: 117:131082
TITLE: [(alkoxyphenyl)alkyl]- and [(alkylphenyl)alkyl]pyridines and -pyridine oxides, methods for their preparation and their use as antiallergic agents
INVENTOR(S): Friebe, Walter Gunar; Kampe, Wolfgang; Linssen, Marcel; Wilhelms, Otto Henning
PATENT ASSIGNEE(S): Boehringer Mannheim GmbH, Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4038335	**A1**	**19920604**	**DE 1990-4038335**	**19901201**
CA 2099603	**AA**	**19920602**	**CA 1991-2099603**	**19911128**
WO 9209598	**A1**	**19920611**	**WO 1991-EP2249**	**19911128**
W: AU, BG, BR, CA, CS, FI, HU, JP, KR, NO, PL, RO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9189574	**A1**	**19920625**	**AU 1991-89574**	**19911128**
EP 559695	**A1**	**19930915**	**EP 1991-920436**	**19911128**
EP 559695	B1	19970122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06503076	**T2**	**19940407**	**JP 1992-500329**	**19911128**
AT 148115	**E**	**19970215**	**AT 1991-920436**	**19911128**
ES 2097822	**T3**	**19970416**	**ES 1991-920436**	**19911128**
US 5399575	**A**	**19950321**	**US 1993-66058**	**19930614**

PRIORITY APPLN. INFO.: DE 1990-4038335 A 19901201
WO 1991-EP2249 A 19911128

OTHER SOURCE(S): CASREACT 117:131082; MARPAT 117:131082
GI



AB Certain [(alkoxyphenyl)alkyl]pyridines, [(alkylphenyl)alkyl]pyridines, or [(alkoxyphenyl)alkyl]pyridine 1-oxides or [(alkylphenyl)alkyl]pyridine 1-oxides are claimed. A process for their prepn. comprises, e.g., the alkylation of a [(hydroxyphenyl)alkyl]pyridine 1-oxide or the phenylation of a methylpyridine 1-oxide deriv. Pharmaceuticals contg. said pyridine derivs. and their use for the treatment of allergies are claimed. Alkylation of 4-[2-(4-hydroxyphenyl)ethenyl]pyridine with bromovaleronitrile gave 5-[4-[2-(4-pyridyl)ethenyl]phenoxy]valeronitrile (I) in 86 yield. The antiallergic activity of I was not tested.

IT **143052-54-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as allergy inhibitor)

RN 143052-54-4 HCAPLUS

CN Acetic acid, [4-[2-(4-pyridinyl)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 33 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1990:178999 HCAPLUS
DOCUMENT NUMBER: 112:178999
TITLE: Morpholines and morpholine N-oxides, medicines containing these compounds and process for their preparation
INVENTOR(S): Reiffen, Manfred; Mark, Michael; Sauter, Robert; Grell, Wolfgang
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 334146	**A1**	**19890927**	**EP 1989-104376**	**19890313**
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3809775	**A1**	**19891005**	**DE 1988-3809775**	**19880323**
JP 01299287	**A2**	**19891204**	**JP 1989-70300**	**19890322**
US 5026702	**A**	**19910625**	**US 1989-327665**	**19890323**

PRIORITY APPLN. INFO.: DE 1988-3809775 A 19880323
OTHER SOURCE(S): CASREACT 112:178999; MARPAT 112:178999

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R1 = (halo-, CF3-, or alkyl-substituted) heteroaryl; R2 = H, OH; R3 = OH, CO2H, alkoxycarbonyl, carbamoyl, (substituted) alkoxy, vinyl; A = (Me- or Et-substituted) C2-3 alkylene; X = bond, O; n = 0, 1], useful as platelet aggregation inhibitors, antidiabetics, antiobesity agents, antihyperlipoproteinemics, and anabolic agents, were prepd. Thus, 2-(6-chloropyridin-2-yl)morpholine and 1-(4-carbomethoxymethoxyphenyl)propan-2-one in MeOH were stirred with HOAc and NaBH3CN to give 84% II. II at 0.3 mg/kg orally in mice reduced blood glucose by 50% and increased blood glycerin by 262%. Numerous formulations of I were given.

IT **126325-27-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as drug)

RN 126325-27-7 HCAPLUS

CN Acetic acid, [4-[2-[2-(6-chloro-2-pyridinyl)-4-morpholinyl]propyl]phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 34 OF 34 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1984:407021 HCAPLUS
DOCUMENT NUMBER: 101:7021
TITLE: Benzo[b]thiophenes
INVENTOR(S): Ong, Helen H.; Profitt, James A.
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA
SOURCE: U.S., 36 pp. Cont.-in-part of U.S. Ser. No. 198,736, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4436748	**A**	**19840313**	**US 1981-256470**	**19810422**
ES 506228	**A1**	**19830101**	**ES 1981-506228**	**19811014**
FI 8103246	**A**	**19820421**	**FI 1981-3246**	**19811016**
EP 50326	**A2**	**19820428**	**EP 1981-108387**	**19811016**
EP 50326	A3	19820721		
EP 50326	B1	19860129		

R: AT, BE, CH, DE, FR, GB, IT, NL, SE

AU 8176547	A1	19820429	AU 1981-76547	19811016
EP 155981	A2	19851002	EP 1984-108392	19811016
EP 155981	A3	19851030		

R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE

AT 17726	E	19860215	AT 1981-108387	19811016
DK 8104606	A	19820421	DK 1981-4606	19811019
NO 8103526	A	19820421	NO 1981-3526	19811019
JP 57122080	A2	19820729	JP 1981-165895	19811019
ZA 8107216	A	19830223	ZA 1981-7216	19811019
HU 26664	O	19830928	HU 1981-3036	19811019
CA 1196923	A1	19851119	CA 1981-388259	19811019
ES 515436	A1	19840701	ES 1982-515436	19820901
ES 524980	A1	19850201	ES 1983-524980	19830816
US 4528399	A	19850709	US 1983-558076	19831205
US 4537976	A	19850827	US 1983-558074	19831205
NO 8404042	A	19820421	NO 1984-4042	19841009
NO 8404043	A	19820421	NO 1984-4043	19841009
NO 8404957	A	19820421	NO 1984-4957	19841211
FI 8501140	A	19850321	FI 1985-1140	19850321
FI 8501141	A	19850321	FI 1985-1141	19850321
US 4672138	A	19870609	US 1986-825725	19860203

PRIORITY APPLN. INFO.:

US 1980-198736	A2	19801020
US 1981-256470	A	19810422
EP 1981-108387	P	19811016
FI 1981-3246	A	19811016
US 1983-558079	A1	19831205

OTHER SOURCE(S): CASREACT 101:7021

GI



AB Benzothiophenes I [R = H, alkyl, cycloalkyl, (un)substituted Ph; R1 = H, alkanoyl, alkyl, cycloalkyl, formyl, hydroxyalkyl, (un)substituted Ph; R2 = (un)substituted alkoxy; R3, R4 = H, halo, alkyl; n = 0-2] were prepd. Thus, 2,3-Cl2C6H3OMe was chlorosulfonylated and the sulfonyl chloride reduced to give the thiophenol II (R5 = H) which was alkylated with Me2CHCHBrCO2H to give the thioether II [R2 = Me2CH(HO2C)CH]. The thioether was cyclized using SOCl2-AlCl3 to give benzothiophenone III. III was reduced to the alc. which was dehydrated to give I (R = H, R1 = Me2CH, R2 = 5-OMe, R3 = 6-Cl, R4 = 7-Cl, n = 0). The latter compd. was demethylated, condensed with BrCH2CO2Et, and hydrolyzed to give I (R = H, R1 = Me2CH, R2 = 5-OCH2CO2H, R3 = 6-Cl, R4 = 7-Cl, n = 0); IV). IV was oxidized with 3-ClC6H4C(O)OOH to give the sulfone (V). At 50 mg/kg in spontaneous hypertensive rats, IV and V decreased blood pressure by 41, 33 mm Hg, resp. At 64 mg/kg in rats V increased urine excretion 2.3-fold.

IT 90340-20-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(diuretic activity of)

RN 90340-20-8 HCAPLUS
CN Acetic acid, [2,3-dichloro-4-[(phenylmethyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




```
=> d his

     (FILE 'HOME' ENTERED AT 16:08:19 ON 20 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 16:08:25 ON 20 DEC 2005
L1             STRUCTURE UPLOADED
L2              50 S L1
L3            1449 S L2 FULL

     FILE 'HCAPLUS' ENTERED AT 16:11:25 ON 20 DEC 2005
L4             102 S L3/THU
L5              34 S L4 AND PD < JULY 2002

=> s l4 and bell, r?/au
           2688 BELL, R?/AU
L6              1 L4 AND BELL, R?/AU

=> d l6, ibib abs hitstr, 1

L6   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Other References

ACCESSION NUMBER: 2004:2698 HCAPLUS
DOCUMENT NUMBER: 140:59519
TITLE: Preparation of (biphenylylalkoxy)- and [(phenylpyridyl)alkoxy]-substituted phenylalkanoic acids and phenoxyalkanoic acids as hPPAR activators for treatment of cardiovascular disease and related disorders
INVENTOR(S): Hamlett, Christopher Charles Frederick; **Bell, Richard**; Beswick, Paul John; Gosmini, Romain Luc Marie; King, Nigel Paul; Patel, Vipulkumar Kantibhai
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000315	A1	20031231	WO 2003-EP6415	20030618

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2487909	AA	20031231	CA 2003-2487909		20030618
EP 1513526	A1	20050316	EP 2003-738056		20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003011931	A	20050405	BR 2003-11931		20030618
JP 2005534672	T2	20051117	JP 2004-514761		20030618
NO 2004005328	A	20050309	NO 2004-5328		20041203
PRIORITY APPLN. INFO.:			GB 2002-14149	A	20020619
			WO 2003-EP6415	W	20030618

OTHER SOURCE(S): MARPAT 140:59519
GI



AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = O or (CH2)n; n = 0-2; R3 R4 = independently H, alkyl, OMe, CF3, allyl, or halo; X1 = O, S, SO2, SO, or CH2; R5 and R6 = independently H, (halo)alkyl, or alkoxyalkyl; or CR5R6 = cycloalkyl; R7 = (un)substituted Ph or 6-membered heteroaryl; and pharmaceutically acceptable salts, solvates, and hydrolyzable esters thereof] were prepd. as human peroxisome proliferator activated receptor (hPPAR) activators. For example, a mixt. of 3-(bromomethyl)-4'-(trifluoromethyl)biphenyl, Et (4-mercapto-2-methylphenoxy)acetate, and polymer-supported diisopropylethylamine in DCM was stirred at room temp. overnight to give the thioether. Sapon. of the ester with aq. NaOH in THF and acidification afforded II. Compds. of the invention showed at least 50% activation of hPPARδ relative to the pos. control at concns. of 10-7 M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, or anorexia nervosa (no data).

IT **638215-22-2P**, [[2-Methyl-4-[[[4'-(trifluoromethyl)biphenyl-3-yl]methyl]thio]phenyl]oxy]acetic acid **638215-23-3P**,

[[2-Methyl-4-[[[4-methyl-4'-(trifluoromethyl)biphenyl-3-yl]methyl]thio]phenyl]oxy]acetic acid **638215-25-5P**, [[2-Methyl-4-[2-[4'-(trifluoromethyl)biphenyl-3-yl]ethyl]phenyl]oxy]acetic acid **638215-26-6P**, [[2-Methyl-4-[[[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]methyl]thio]phenyl]oxy]acetic acid **638215-27-7P**, [[2-Methyl-4-[[1-[4'-(trifluoromethyl)biphenyl-3-yl]ethyl]thio]phenyl]oxy]acetic acid **638215-28-8P**, [[2-Methyl-4-[[1-[4'-(trifluoromethyl)biphenyl-4-yl]ethyl]thio]phenyl]oxy]acetic acid **638215-29-9P**, 2-Methyl-2-[[2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]propanoic acid **638215-30-2P**, [[2-Methyl-4-[[1-[4'-(trifluoromethyl)biphenyl-3-yl]pentyl]oxy]phenyl]oxy]acetic acid **638215-31-3P**, [[4-[[1-(4'-Chlorobiphenyl-3-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-32-4P**, [[2-Methyl-4-[[1-[4'-(trifluoromethyl)biphenyl-4-yl]pentyl]oxy]phenyl]oxy]acetic acid **638215-33-5P**, [[4-[[1-(4'-Chlorobiphenyl-4-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-34-6P**, [[2-Methyl-4-[[(1R)-1-[4'-(trifluoromethyl)biphenyl-4-yl]pentyl]thio]phenyl]oxy]acetic acid **638215-35-7P**, [[2-Methyl-4-[[(1S)-1-[4'-(trifluoromethyl)biphenyl-4-yl]pentyl]thio]phenyl]oxy]acetic acid **638215-36-8P**, [[2-Methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid **638215-37-9P**, [[2-Methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid **638215-38-0P**, [[2-Methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]thio]phenyl]oxy]acetic acid **638215-39-1P**, [[2-Methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]thio]phenyl]oxy]acetic acid **638215-40-4P**, [[2-Methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]sulfinyl]phenyl]oxy]acetic acid **638215-41-5P**, [[2-Methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]sulfonyl]phenyl]oxy]acetic acid **638215-43-7P**, [[2-Methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]butyl]oxy]phenyl]oxy]acetic acid **638215-45-9P**, [[4-[[1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid **638215-47-1P**, [[4-[[1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-48-2P**, [[2-Methyl-4-[[1-[6-[4-(methyloxy)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid **638215-49-3P**, [[4-[[1-[6-[4-(Ethyloxy)phenyl]-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-50-6P**, [[2-Methyl-4-[[1-[6-(4-methylphenyl)-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid **638215-51-7P**, [[4-[[1-[6-(3,4-Dichlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-52-8P**, [[2-Methyl-4-[[1-[6-[3-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid **638215-53-9P**, [[2-Methyl-4-[[1-(6-phenyl-2-pyridinyl)pentyl]oxy]phenyl]oxy]acetic acid **638215-54-0P**, [[4-[[1-[6-(4-Acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-55-1P**, [[4-[[1-[6-(4-Fluorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-56-2P**, [[4-[[1-[6-(4-Cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-57-3P**, [[2-Methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]hexyl]oxy]phenyl]oxy]acetic acid **638215-58-4P**, [[2-Methyl-4-[[4-methyl-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid **638215-59-5P**, [[2-Methyl-4-[[3-methyl-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]butyl]oxy]phenyl]oxy]acetic acid **638215-60-8P**, [[4-[[1-(Biphenyl-3-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid

638215-61-9P, [[4-[[1-[4'-(Ethyloxy)biphenyl-3-yl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-62-0P, [[4-[[1-(4'-Cyanobiphenyl-3-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-63-1P, [[2-Ethyl-4-[[1-(6-phenyl-2-pyridinyl)pentyl]oxy]phenyl]oxy]acetic acid 638215-64-2P, [[4-[[1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-ethylphenyl]oxy]acetic acid 638215-65-3P, [[2-Ethyl-4-[[1-[6-[4-(ethyloxy)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-66-4P, [[4-[[1-[6-(4-Cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-ethylphenyl]oxy]acetic acid 638215-67-5P, [[2-Ethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-69-7P, [[4-[[(1R)-1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-70-0P , [[4-[[(1R)-1-[6-(4-Cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-71-1P, [[2-Methyl-4-[[(1R)-1-[6-[4-(methyloxy)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-72-2P, [[4-[[(1R)-1-[6-(4-Acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-73-3P , [[4-[[(1R)-1-[6-[4-Acetyl-3-(methyloxy)phenyl]-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-74-4P, [[4-[[(1S)-1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-75-5P, [[4-[[(1S)-1-[6-(4-Cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-76-6P , [[2-Methyl-4-[[(1S)-1-[6-[4-(methyloxy)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-77-7P, [[4-[[(1S)-1-[6-(4-Acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-78-8P, [[4-[[(1S)-1-[6-[4-Acetyl-3-(methyloxy)phenyl]-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-79-9P, [[2-Methyl-4-[[(1R)-3-(methyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]propyl]oxy]phenyl]oxy]acetic acid 638215-80-2P, [[4-[[(1R)-1-[6-(4-Chlorophenyl)-2-pyridinyl]-3-(methyloxy)propyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-81-3P, [[2-Methyl-4-[[(1S)-3-(methyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]propyl]oxy]phenyl]oxy]acetic acid 638215-82-4P, [[4-[[(1S)-1-[6-(4-Chlorophenyl)-2-pyridinyl]-3-(methyloxy)propyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-83-5P, [[4-[[(1R)-2-(Ethyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-84-6P, [[4-[[(1R)-2-(Ethyloxy)-1-[6-[4-(methyloxy)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-85-7P, [[4-[[(1R)-1-[6-(4-Acetylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-86-8P, [[4-[[(1R)-1-[6-(4-Cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-87-9P, [[4-[[(1R)-1-[6-(4-Chlorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-88-0P , [[4-[[(1S)-2-(Ethyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-89-1P , [[4-[[(1S)-2-(Ethyloxy)-1-[6-[4-(methyloxy)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-90-4P , [[4-[[(1S)-1-[6-(4-Acetylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-91-5P, [[4-[[(1S)-1-[6-(4-Cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-92-6P, [[4-[[(1S)-1-[6-(4-Chlorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-93-7P , [[4-[[(1R)-2-(Ethyloxy)-1-[6-(3-fluoro-4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-94-8P , [[4-[[(1R)-2-(Ethyloxy)-1-[6-(4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-95-9P, [[4-[[(1R)-2-(Ethyloxy)-1-[6-[4-(1-methylethyl)phenyl]-2-pyridinyl]ethyl]oxy]-2-

methylphenyl]oxy]acetic acid **638215-96-0P**, [[4-[[(1R)-1-[6-(4-Cyano-3-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-97-1P**, [[4-[[(1R)-2-(Ethyloxy)-1-[6-[4-(ethyloxy)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-98-2P**, [[4-[[(1R)-2-(Ethyloxy)-1-[6-(2-fluoro-4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638215-99-3P**, [[4-[[(1R)-2-(Ethyloxy)-1-[6-(4-fluorophenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-00-9P**, [[4-[[(1R)-2-(Ethyloxy)-1-[6-[4-[(1-methylethyl)oxy]phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-01-0P**, [[4-[[(1R)-1-[6-(4-Chloro-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-02-1P**, [[4-[[(1R)-1-[6-(3-Chloro-4-cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-03-2P**, [[4-[[(1R)-1-[6-(4-Cyano-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-04-3P**, [[4-[[(1R)-2-(Ethyloxy)-1-[6-[3-fluoro-4-(methyloxy)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-05-4P**, [[4-[[(1R)-1-[6-(4-Cyano-2-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-06-5P**, [[4-[[(1R)-1-[6-(4-Cyano-2-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-07-6P**, [[4-[[(1S)-2-(Ethyloxy)-1-[6-(3-fluoro-4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-08-7P**, [[4-[[(1S)-2-(Ethyloxy)-1-[6-(4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-09-8P**, [[4-[[(1S)-2-(Ethyloxy)-1-[6-[4-(1-methylethyl)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-10-1P**, [[4-[[(1S)-1-[6-(4-Cyano-3-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-11-2P**, [[4-[[(1S)-2-(Ethyloxy)-1-[6-[4-(ethyloxy)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-12-3P**, [[4-[[(1S)-2-(Ethyloxy)-1-[6-(2-fluoro-4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-13-4P**, [[4-[[(1S)-2-(Ethyloxy)-1-[6-(4-fluorophenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-14-5P**, [[4-[[(1S)-2-(Ethyloxy)-1-[6-[4-[(1-methylethyl)oxy]phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-15-6P**, [[4-[[(1S)-1-[6-(4-Chloro-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-16-7P**, [[4-[[(1S)-1-[6-(3-Chloro-4-cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-17-8P**, [[4-[[(1S)-1-[6-(4-Cyano-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-18-9P**, [[4-[[(1S)-2-(Ethyloxy)-1-[6-[3-fluoro-4-(methyloxy)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-19-0P**, [[4-[[(1S)-1-[6-(4-Cyano-2-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-20-3P**, [[4-[[(1S)-1-[6-[4-Cyano-3-(methyloxy)phenyl]-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-58-7P**, [[2-Methyl-4-[[1-[2-methyl-4'-(trifluoromethyl)biphenyl-3-yl]pentyl]oxy]phenyl]oxy]acetic acid **638216-59-8P**, [[4-[[1-(4'-Chloro-2-methylbiphenyl-3-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-60-1P**, [[4-[[1-(2,4'-Dimethylbiphenyl-3-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-61-2P**, [[4-[[1-(4'-Cyano-2-methylbiphenyl-3-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid **638216-62-3P**, [[2-Methyl-4-[[1-[2-methyl-4'-(methyloxy)biphenyl-3-yl]pentyl]oxy]phenyl]oxy]acetic acid **638216-63-4P**, [[4-[[1-(4'-Fluoro-2-methylbiphenyl-3-yl)pentyl]oxy]-2-

methylphenyl]oxy]acetic acid **638216-64-5P**, [[2-Methyl-4-[[2-(propyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]oxy]phenyl]oxy]acetic acid **638216-65-6P**, [[4-[[2-(Ethyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]thio]-2-methylphenyl]oxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(hPPAR activator; prepn. of (aryloxy)phenylalkanoic acids and (aryloxy)phenoxyalkanoic acids as hPPAR activators for treatment of cardiovascular disease and related disorders)

RN 638215-22-2 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-23-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[4-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-25-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[2-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-26-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-27-7 HCAPLUS

CN Acetic acid, [2-methyl-4-[[1-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-28-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-29-9 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-30-2 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-31-3 HCAPLUS
CN Acetic acid, [4-[[1-(4'-chloro[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-32-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-

yl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-33-5 HCAPLUS
CN Acetic acid, [4-[[1-(4'-chloro[1,1'-biphenyl]-4-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-34-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1R)-1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]pentyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-35-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1S)-1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]pentyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-36-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-37-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-38-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-39-1 HCAPLUS

CN Acetic acid, [2-methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-40-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]sulfinyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-41-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-43-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]butoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-45-9 HCAPLUS
CN Acetic acid, [4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-47-1 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-48-2 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-methoxyphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-49-3 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-ethoxyphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-50-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-(4-methylphenyl)-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-51-7 HCAPLUS
CN Acetic acid, [4-[[1-[6-(3,4-dichlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-52-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-[3-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-53-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-(6-phenyl-2-pyridinyl)pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-54-0 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-

methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-55-1 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-fluorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-56-2 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-57-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]hexyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-58-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[4-methyl-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-59-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[3-methyl-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]butoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-60-8 HCAPLUS
CN Acetic acid, [4-[(1-[1,1'-biphenyl]-3-ylpentyl)oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-61-9 HCAPLUS
CN Acetic acid, [4-[[1-(4'-ethoxy[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-62-0 HCAPLUS
CN Acetic acid, [4-[[1-(4'-cyano[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-63-1 HCAPLUS
CN Acetic acid, [2-ethyl-4-[[1-(6-phenyl-2-pyridinyl)pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-64-2 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-65-3 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-ethoxyphenyl)-2-pyridinyl]pentyl]oxy]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-66-4 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-67-5 HCAPLUS
CN Acetic acid, [2-ethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-69-7 HCAPLUS
CN Acetic acid, [4-[[(1R)-1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-70-0 HCAPLUS
CN Acetic acid, [4-[[(1R)-1-[6-(4-cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-71-1 HCAPLUS
CN Acetic acid, [4-[[(1R)-1-[6-(4-methoxyphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-72-2 HCAPLUS
CN Acetic acid, [4-[[(1R)-1-[6-(4-acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-73-3 HCAPLUS
CN Acetic acid, [4-[[(1R)-1-[6-(4-acetyl-3-methoxyphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-74-4 HCAPLUS
CN Acetic acid, [4-[[(1S)-1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-

methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-75-5 HCAPLUS
CN Acetic acid, [4-[[(1S)-1-[6-(4-cyanophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-76-6 HCAPLUS
CN Acetic acid, [4-[[(1S)-1-[6-(4-methoxyphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-77-7 HCAPLUS
CN Acetic acid, [4-[[(1S)-1-[6-(4-acetylphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-78-8 HCAPLUS
CN Acetic acid, [4-[[(1S)-1-[6-(4-acetyl-3-methoxyphenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-79-9 HCAPLUS
CN Acetic acid, [4-[(1R)-3-methoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-

pyridinyl]propoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-80-2 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-chlorophenyl)-2-pyridinyl]-3-methoxypropoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-81-3 HCAPLUS
CN Acetic acid, [4-[(1S)-3-methoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]propoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-82-4 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-chlorophenyl)-2-pyridinyl]-3-methoxypropoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-83-5 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-84-6 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(4-methoxyphenyl)-2-pyridinyl]ethoxy]-

2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-85-7 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-acetylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-86-8 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-87-9 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-chlorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-88-0 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-89-1 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(4-methoxyphenyl)-2-pyridinyl]ethoxy]-

2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-90-4 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-acetylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-91-5 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-92-6 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-chlorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-93-7 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(3-fluoro-4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-94-8 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(4-methylphenyl)-2-pyridinyl]ethoxy]-2-

methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-95-9 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-[4-(1-methylethyl)phenyl]-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-96-0 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-3-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-97-1 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(4-ethoxyphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-98-2 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(2-fluoro-4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-99-3 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(4-fluorophenyl)-2-pyridinyl]ethoxy]-2-

methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-00-9 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-[4-(1-methylethoxy)phenyl]-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-01-0 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-chloro-3-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-02-1 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(3-chloro-4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-03-2 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-3-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-04-3 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(3-fluoro-4-methoxyphenyl)-2-

pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-05-4 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-2-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-06-5 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-2-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-07-6 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(3-fluoro-4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-08-7 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-09-8 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-[4-(1-methylethyl)phenyl]-2-

pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-10-1 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-3-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-11-2 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(4-ethoxyphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-12-3 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(2-fluoro-4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-13-4 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(4-fluorophenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-14-5 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-[4-(1-methylethoxy)phenyl]-2-

pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-15-6 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-chloro-3-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-16-7 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(3-chloro-4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-17-8 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-3-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-18-9 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(3-fluoro-4-methoxyphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-19-0 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-2-fluorophenyl)-2-pyridinyl]-2-

ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-20-3 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-3-methoxyphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-58-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638216-59-8 HCAPLUS
CN Acetic acid, [4-[[1-(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638216-60-1 HCAPLUS
CN Acetic acid, [4-[[1-(2,4'-dimethyl[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638216-61-2 HCAPLUS
CN Acetic acid, [4-[[1-(4'-cyano-2-methyl[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638216-62-3 HCAPLUS
CN Acetic acid, [4-[[1-(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638216-63-4 HCAPLUS
CN Acetic acid, [4-[[1-(4'-fluoro-2-methyl[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638216-64-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[2-propoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638216-65-6 HCAPLUS
CN Acetic acid, [4-[[2-ethoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 16:08:19 ON 20 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 16:08:25 ON 20 DEC 2005
L1             STRUCTURE UPLOADED
L2              50 S L1
L3            1449 S L2 FULL

     FILE 'HCAPLUS' ENTERED AT 16:11:25 ON 20 DEC 2005
L4             102 S L3/THU
L5              34 S L4 AND PD < JULY 2002
L6               1 S L4 AND BELL, R?/AU

=> s l4 not l6
L7            101 L4 NOT L6

=> s l7 and beswick, p?/au
               57 BESWICK, P?/AU
L8              2 L7 AND BESWICK, P?/AU

=> d l8, ibib abs hitstr, 1-2

L8   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 2002:888731 HCAPLUS

DOCUMENT NUMBER: 137:384743
TITLE: Preparation of furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
INVENTOR(S): **Beswick, Paul John**; Hamlett, Christopher Charles Frederick; Patel, Vipulkumar; Sierra, Michael Lawrence; Ramsden, Nigel Grahame
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092590	A1	20021121	WO 2002-GB2152	20020509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446797	AA	20021121	CA 2002-2446797	20020509
EP 1392674	A1	20040303	EP 2002-722506	20020509
EP 1392674	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1507442	A	20040623	CN 2002-809694	20020509
BR 2002009468	A	20040803	BR 2002-9468	20020509
JP 2004534035	T2	20041111	JP 2002-589475	20020509
AT 301649	E	20050815	AT 2002-722506	20020509
ZA 2003008352	A	20050127	ZA 2003-8352	20031027
NO 2003004986	A	20031110	NO 2003-4986	20031110
US 2004157890	A1	20040812	US 2004-476194	20040323
PRIORITY APPLN. INFO.:			GB 2001-11523 A	20010511
			WO 2002-GB2152 W	20020509

OTHER SOURCE(S): MARPAT 137:384743
GI



AB The title compds. [I; X1 = O, S, NH, NMe, alkyl; R1, R2 = H, alkyl; R3-R5 = H, Me, OMe, CF3, halo; m = 0-3; X2 = (CR10R11)n, O, S, OCH2; n = 1-2; R6, R7, R10, R11 = H, F, alkyl, etc.; one of Y and Z = CH, the other = S, O with the proviso that Y cannot be substituted and Z can only be substituted when it is carbon; R8 = (un)substituted Ph, pyridyl (wherein the N is in position 2 or 3) with the provision that when R3 = pyridyl, the N is unsubstituted; R9 = alkyl, CF3, CH2D (D = N-substituted piperazino, furyl, piperidino, etc.); R26, R27 = H, alkyl; or R26 and R27, together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring] and their pharmaceutically acceptable salts, useful for the treatment of a hPPAR mediated disease or condition such as dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, inflammation and anorexia nervosa, were prepd. Thus, coupling {5-[4-(trilfuoromethyl)phenyl]-3-furyl}methanol with Et (4-mercapto-2-methylphenoxy)acetate followed by hydrolysis of the resulting ester afforded the acid II.

IT 439135-02-1P 476154-08-2P 476154-09-3P
476154-10-6P 476154-11-7P 476154-12-8P
476154-13-9P 476154-14-0P 476154-15-1P
476154-16-2P 476154-17-3P 476154-18-4P
476154-19-5P 476154-20-8P 476154-21-9P
476154-22-0P 476154-23-1P 476154-24-2P
476154-25-3P 476154-26-4P 476154-27-5P
476154-28-6P 476154-29-7P 476154-30-0P
476154-31-1P 476154-38-8P 476154-39-9P
476154-40-2P 476154-41-3P 476154-42-4P
476154-43-5P 476154-44-6P 476154-45-7P
476154-46-8P 476154-47-9P 476154-48-0P
476154-49-1P 476154-50-4P 476154-51-5P
476154-52-6P 476154-53-7P 476154-54-8P
476154-55-9P 476154-56-0P 476154-57-1P
476154-58-2P 476154-59-3P 476154-60-6P
476154-61-7P 476154-62-8P 476154-64-0P
476154-65-1P 476154-66-2P 476154-67-3P
476154-68-4P 476154-69-5P 476154-71-9P
476154-72-0P 476154-75-3P 476154-78-6P
476154-79-7P 476154-80-0P 476154-83-3P
476154-84-4P 476154-85-5P 476154-86-6P
476154-88-8P 476154-90-2P 476154-92-4P
476154-94-6P 476154-96-8P 476154-98-0P

476155-00-7P 476155-02-9P 476155-09-6P
476155-10-9P 476155-11-0P 476155-12-1P
476155-13-2P 476155-14-3P 476156-38-4P
476156-39-5P 476156-41-9P 476156-48-6P
476156-49-7P 476156-50-0P 476156-51-1P
476156-52-2P 476156-53-3P 476156-54-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of furan and thiophene derivs. that activate human peroxisome proliferator activated receptors)

RN 439135-02-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-08-2 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-09-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-10-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-11-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-3-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-12-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-13-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-14-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-15-1 HCAPLUS
CN Acetic acid, [4-[[[5-(4-chlorophenyl)-2-(trifluoromethyl)-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-16-2 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-17-3 HCAPLUS
CN Acetic acid, [4-[[[5-(4-chlorophenyl)-2-methyl-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-18-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[3-methyl-5-[5-(trifluoromethyl)-2-pyridinyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-19-5 HCAPLUS
CN Acetic acid, [4-[[5-(4-chlorophenyl)-2-methyl-3-furanyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-20-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[2-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-21-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-22-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-23-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-furanyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-24-2 HCAPLUS
CN Acetic acid, [4-[[5-(4-chlorophenyl)-2-(trifluoromethyl)-3-furanyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-25-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-26-4 HCAPLUS
CN Propanoic acid, 2-[4-[[5-(4-chlorophenyl)-2-methyl-3-furanyl]methoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 476154-27-5 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-28-6 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[2-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-29-7 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-30-0 HCAPLUS
CN Propanoic acid, 2-[4-[[5-(4-chlorophenyl)-2-(trifluoromethyl)-3-furanyl]methoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 476154-31-1 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-38-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[2-(4-pyridinyl)ethyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 476154-39-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[[(1-methylethyl)thio]methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-40-2 HCAPLUS
CN Acetic acid, [4-[[[2-[[(1H-benzimidazol-2-ylmethyl)thio]methyl]-5-[4-

(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI)
(CA INDEX NAME)



RN 476154-41-3 HCAPLUS
CN Acetic acid, [4-[[[2-[[(3,5-dimethylphenyl)thio]methyl]-5-[4-
(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI)
(CA INDEX NAME)



RN 476154-42-4 HCAPLUS
CN Acetic acid, [4-[[[2-[[(2,4-difluorophenyl)thio]methyl]-5-[4-
(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI)
(CA INDEX NAME)



RN 476154-43-5 HCAPLUS
CN Acetic acid, [4-[[[2-[[(2-furanylmethyl)thio]methyl]-5-[4-
(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI)
(CA INDEX NAME)



RN 476154-44-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[[(phenylmethyl)thio]methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-45-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[[methyl(1-methylethyl)amino]methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-46-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-(phenoxymethyl)-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-47-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[(methylphenylamino)methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-48-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-(2-methylpropyl)-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-49-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[2-(4-methylphenyl)ethyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-50-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-(3-methylbutyl)-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-51-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[[methyl(2-phenylethyl)amino]methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-52-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[[methyl(3-pyridinylmethyl)amino]methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-53-7 HCAPLUS
CN Acetic acid, [4-[[[2-[[[(3,5-dimethoxyphenyl)methyl]methylamino]methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-54-8 HCAPLUS
CN Acetic acid, [4-[[[2-[(cyclohexylmethylamino)methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-55-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-[[(1-methylethyl)thio]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-56-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-(phenoxymethyl)-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-57-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-[[(phenylmethyl)thio]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-58-2 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-[[4-(trifluoromethyl)phenoxy]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-59-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-[[4-(2-phenylethyl)phenoxy]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-60-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-[[(4'-methyl[1,1'-biphenyl]-4-yl)oxy]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-61-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-[(methylphenylamino)methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-62-8 HCAPLUS
CN Acetic acid, [4-[[[3-ethyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-64-0 HCAPLUS
CN Acetic acid, [4-[[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-65-1 HCAPLUS
CN Acetic acid, [4-[[[5-(4-chlorophenyl)-2-methyl-3-furanyl]methyl]thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-66-2 HCAPLUS
CN Acetic acid, [4-[2-[5-(4-chlorophenyl)-2-methyl-3-furanyl]ethyl]-2-methylphenoxy]-, compd. with hydrochloric acid (1:1) (9CI) (CA INDEX NAME)



HCl

RN 476154-67-3 HCAPLUS

CN Acetic acid, [2-methyl-4-[2-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-68-4 HCAPLUS

CN Acetic acid, [2-methyl-4-[2-[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-69-5 HCAPLUS

CN Acetic acid, [4-[2-[5-(4-chlorophenyl)-2-(trifluoromethyl)-3-furanyl]ethyl]-2-methylphenoxy]-, sodium salt (9CI) (CA INDEX NAME)



RN 476154-71-9 HCAPLUS
CN Acetic acid, [2-(1,1-dimethylethyl)-6-methyl-4-[2-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-72-0 HCAPLUS
CN Acetic acid, [2,6-dimethyl-4-[2-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-75-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[3-methyl-5-[4-(trifluoromethoxy)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-78-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[3-methyl-5-[6-(trifluoromethyl)-3-pyridinyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-79-7 HCAPLUS
CN Acetic acid, [4-[[5-(5-chloro-2-pyridinyl)-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-80-0 HCAPLUS
CN Acetic acid, [4-[2-[5-(4-cyano-3-fluorophenyl)-3-methyl-2-thienyl]ethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-83-3 HCAPLUS
CN Acetic acid, [2-ethyl-4-[[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-84-4 HCAPLUS
CN Acetic acid, [2-(1-methylethyl)-4-[[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-85-5 HCAPLUS
CN Acetic acid, [2-chloro-4-[[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-86-6 HCAPLUS
CN Acetic acid, [2-bromo-4-[[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-88-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-methyl-5-[4-(trifluoromethoxy)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-90-2 HCAPLUS
CN Acetic acid, [4-[[5-[2,5-difluoro-4-(trifluoromethyl)phenyl]-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-92-4 HCAPLUS
CN Acetic acid, [4-[[5-[2,3-difluoro-4-(trifluoromethyl)phenyl]-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-94-6 HCAPLUS
CN Acetic acid, [4-[[5-[2-fluoro-4-(trifluoromethyl)phenyl]-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-96-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[5-[4-(trifluoromethyl)phenyl]-3-thienyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-98-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[phenyl[5-[4-(trifluoromethyl)phenyl]-3-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476155-00-7 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[phenyl[5-[4-(trifluoromethyl)phenyl]-3-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476155-02-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476155-09-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[3-[[(1-methylethyl)thio]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476155-10-9 HCAPLUS

CN Acetic acid, [2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-3-[(2,3,6-trimethylphenoxy)methyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476155-11-0 HCAPLUS

CN Acetic acid, [2-methyl-4-[[[3-[[[6-methyl-2-(1-methylethyl)-4-pyrimidinyl]oxy]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476155-12-1 HCAPLUS

CN Acetic acid, [2-methyl-4-[[[2-[(2-quinolinylthio)methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476155-13-2 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[(1H-1,2,4-triazol-3-ylthio)methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476155-14-3 HCAPLUS
CN Acetic acid, [4-[[[2-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476156-38-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3-methyl-4-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476156-39-5 HCAPLUS
CN Acetic acid, [4-[2-[5-(4-chlorophenyl)-2-[[(phenylmethyl)thio]methyl]-3-furanyl]ethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476156-41-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-2-furanyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476156-48-6 HCAPLUS
CN Acetic acid, [4-[[[2-[[[4-(1,1-dimethylethyl)phenyl]thio]methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476156-49-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[[methyl(3-pyridinylmethyl)amino]methyl]-5-

[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]-,
monohydrochloride (9CI) (CA INDEX NAME)



RN 476156-50-0 HCAPLUS
CN Acetic acid, [4-[[[2-[(cyclohexylmethylamino)methyl]-5-[4-
(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]-2-methylphenoxy]-,
hydrochloride (9CI) (CA INDEX NAME)



RN 476156-51-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[[methyl(2-phenylethyl)amino]methyl]-5-[4-
(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]-, hydrochloride
(9CI) (CA INDEX NAME)



HCl

RN 476156-52-2 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476156-53-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[5-[4-(trifluoromethyl)phenyl]-3-furanyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476156-54-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[3-methyl-5-[4-(1,1,2-trifluoroethoxy)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:487541 HCAPLUS
DOCUMENT NUMBER: 137:63239
TITLE: Thia- and oxazoles and their use as hPPAR delta agonists
INVENTOR(S): **Beswick, Paul John**; Patel, Vipulkumar; Sierra, Michael Lawrence
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050048	A1	20020627	WO 2001-EP14887	20011218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002029669	A5	20020701	AU 2002-29669	20011218
EP 1343772	A1	20030917	EP 2001-990571	20011218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004102493	A1	20040527	US 2003-451307	20031117
PRIORITY APPLN. INFO.:			GB 2000-31109 A	20001220
			WO 2001-EP14887 W	20011218

OTHER SOURCE(S): MARPAT 137:63239
GI



AB I (e.g. [4-[1,1-difluoro-3-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propyl]-2-methylphenoxy]acetic acid) or pharmaceutically acceptable salts and solvates thereof are claimed. R1 and R2 are independently H or C1-3alkyl, m is 0-3; X1 is NH, NCH3, O, S; R3, R4 and R5 are independently H, CH3, CF3, OCH3, allyl or halogen; X2 is (CR10R11)n wherein n is 1 or 2; R10 and R11 independently represent H, F or C1-16alkyl; R26 and R27 are independently H, C1-3 alkyl or R26 and R27 together with the C atom to which they are bonded form a 3-5 membered

cycloalkyl ring. R6 and R7 independently represent H, F or C1-16alkyl; R9 is C1-6alkyl or CF3; one of Y and Z is N, the other is S or O; each R8 independently represents CF3, OCH3, CH3 or halogen; y is 0-5. Use of I for the manuf. of a medicament for the prevention or treatment of a hPPAR (human peroxisome proliferator activated receptor)-mediated disease or condition, such as dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, type II diabetes mellitus, type 1 diabetes, insulin resistance hyperlipidemia, obesity, anorexia, bulimia, inflammation and anorexia nervosa. Binding and transfection assays are described but no results are given. Although the methods of prepn. are not claimed, 35 example prepns. of intermediates and claimed compds. are included.

IT **439135-02-1P**, [2-Methyl-4-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethyl]phenoxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(thia- and oxazoles and use as hPPAR delta agonists)

RN 439135-02-1 HCAPLUS

CN Acetic acid, [2-methyl-4-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 16:08:19 ON 20 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 16:08:25 ON 20 DEC 2005
L1             STRUCTURE UPLOADED
L2              50 S L1
L3            1449 S L2 FULL

     FILE 'HCAPLUS' ENTERED AT 16:11:25 ON 20 DEC 2005
L4             102 S L3/THU
L5              34 S L4 AND PD < JULY 2002
L6               1 S L4 AND BELL, R?/AU
L7             101 S L4 NOT L6
L8               2 S L7 AND BESWICK, P?/AU

=> s l4 not l8
L9             100 L4 NOT L8

=> s l9 not l6
```

```
L10         99 L9 NOT L6

=> s l10 and gosmini, r?/au
            16 GOSMINI, R?/AU
L11          1 L10 AND GOSMINI, R?/AU

=> d l11, ibib abs hitstr, 1

L11  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | More References

ACCESSION NUMBER: 2002:615588 HCAPLUS
DOCUMENT NUMBER: 137:169510
TITLE: Preparation of thiazole and oxazole derivatives for treating human PPAR related disorders
INVENTOR(S): Cadilla, Rodolfo; **Gosmini, Romain Luc Marie**; Lambert, Millard Hurst, III; Sierra, Michael Lawrence
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002062774	A1	20020815	WO 2001-US49230		20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2432188	AA	20020815	CA 2001-2432188		20011219
EP 1343773	A1	20030917	EP 2001-994305		20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001016370	A	20031209	BR 2001-16370		20011219
JP 2004518702	T2	20040624	JP 2002-562729		20011219
CN 1527822	A	20040908	CN 2001-822309		20011219
NZ 526543	A	20041126	NZ 2001-526543		20011219
ZA 2003004679	A	20041004	ZA 2003-4679		20030617
NO 2003002801	A	20030804	NO 2003-2801		20030619
US 2004063964	A1	20040401	US 2003-451313		20031020
PRIORITY APPLN. INFO.:			GB 2000-31107	A	20001220
			WO 2001-US49230	W	20011219

OTHER SOURCE(S): MARPAT 137:169510
GI



AB Title compds. I [wherein R1 and R2 = independently H, or alkyl; or CR1R2 = cycloalkyl; and at least one or R1 and R2 ? H; X2 = O, S, or (CR10R11)n; n = 1-2; R3-R5 = independently H, alkyl, OMe,CF3, allyl, or halo; R10 and R11 = independently H, F, or alkyl; one of Y and Z is N, and the other is S or O; R6 and R7 = independently H, Ph, PhCH2, F, OH, alkyl, or allyl; or CR6R7 = CO; R9 = H, CF3, or Me; R8 = independently CF3, alkyl, OMe, or halo; m = 0-5; or pharmaceutically acceptable salts, solvates, or hydrolyzable esters thereof] were prepd. as selective human peroxisome proliferator-activated receptor (hPPAR) activators. For example, Et 2-(4-hydroxy-2-methylphenoxy)-2-methylpropanoate was condensed with (R)-α,4-dimethyl-2-(4-trifluoromethylphenyl)-5-thiazolemethanol using Mitsunobu protocol to give the Et ester of (S)-II (52.5%). Sapon. afforded the acid (S)-II (52.5%), which activated hPPARα, hPPARδ, and hPPARγ with EC50 values of 16 nM, 3 nM, and 7000 nM, resp. I are useful for the treatment hPPAR mediated diseases or conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, and anorexia nervosa (no data).

IT **447406-78-2P**, 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid **447406-80-6P**, 2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethoxy]phenoxy]propionic acid **447406-82-8P**, [2-Methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethoxy]phenoxy]acetic acid **447406-84-0P**, 2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(3-fluoro-4-trifluoromethylphenyl)thiazol-5-yl]ethoxy]phenoxy]propionic acid **447406-86-2P**, (S)-2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethoxy]phenoxy]propionic acid **447406-88-4P**, (R)-2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethoxy]phenoxy]propionic acid **447406-90-8P**, 2-[4-[1-[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropionic acid **447406-92-0P**, 2-[4-[1-[2-(3,4-Dichlorophenyl)-4-methylthiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropionic acid **447406-94-2P**, 2-[4-[1-[2-(4-Ethylphenyl)-4-methylthiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropionic acid **447406-96-4P**, 2-[4-[1-[2-(2-Fluoro-4-trifluoromethylphenyl)-4-methylthiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropionic acid **447406-98-6P**, 2-Methyl-2-[2-methyl-4-[1-[2-(4-trifluoromethylphenyl)thiazol-5-yl]ethoxy]phenoxy]propionic acid **447407-00-3P**, 2-Methyl-2-[2-methyl-4-[1-methyl-1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethoxy]phenoxy]propionic acid

447407-02-5P, 2-Methyl-2-[2-methyl-4-[1-methyl-1-[2-(4-trifluoromethylphenyl)thiazol-5-yl]ethoxy]phenoxy]propionic acid
447407-04-7P, 2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]propoxy]phenoxy]propionic acid
447407-06-9P, (R)-2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]propoxy]phenoxy]propionic acid
447407-08-1P, (S)-2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]propoxy]phenoxy]propionic acid
447407-10-5P, 2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]but-3-enyloxy]phenoxy]propionic acid
447407-12-7P, 2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]butoxy]phenoxy]propionic acid
447407-14-9P, 2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]pentyloxy]phenoxy]propionic acid
447407-16-1P, 2-[4-[Cyclopentyl[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]methoxy]-2-methylphenoxy]-2-methylpropionic acid 447407-18-3P, 2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]phenylmethoxy]phenoxy]propionic acid 447407-20-7P, 2-Methyl-2-[2-methyl-4-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethoxy]phenoxy]propionic acid
447407-22-9P, 2-Methyl-2-[2-methyl-4-[1-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]-2-phenylethoxy]phenoxy]propionic acid
447407-24-1P 447407-26-3P 447407-28-5P
447407-30-9P 447407-32-1P 447407-34-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR activator; prepn. of thiazole and oxazole derivs. for treating human PPAR related disorders)

RN 447406-78-2 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 447406-80-6 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447406-82-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447406-84-0 HCAPLUS
CN Propanoic acid, 2-[4-[1-[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]ethoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 447406-86-2 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[(1S)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX

NAME)

Absolute stereochemistry. Rotation (-).



RN 447406-88-4 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[(1R)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 447406-90-8 HCAPLUS
CN Propanoic acid, 2-[4-[1-[2-(4-chlorophenyl)-4-methyl-5-thiazolyl]ethoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 447406-92-0 HCAPLUS
CN Propanoic acid, 2-[4-[1-[2-(3,4-dichlorophenyl)-4-methyl-5-thiazolyl]ethoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 447406-94-2 HCAPLUS
CN Propanoic acid, 2-[4-[1-[2-(4-ethylphenyl)-4-methyl-5-thiazolyl]ethoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 447406-96-4 HCAPLUS
CN Propanoic acid, 2-[4-[1-[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]ethoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 447406-98-6 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-00-3 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-methyl-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-02-5 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-methyl-1-[2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-04-7 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]propoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-06-9 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[(1R)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]propoxy]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 447407-08-1 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[(1S)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]propoxy]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 447407-10-5 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]-3-butenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-12-7 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]butoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-14-9 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[1-[4-methyl-2-[4-

(trifluoromethyl)phenyl]-5-thiazolyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-16-1 HCAPLUS

CN Propanoic acid, 2-[4-[cyclopentyl[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 447407-18-3 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]phenylmethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-20-7 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-22-9 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]-2-phenylethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-24-1 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-26-3 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-28-5 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[1-methyl-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-30-9 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[1-methyl-1-[2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-32-1 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]propyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 447407-34-3 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[2-methyl-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]propoxy]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 16:08:19 ON 20 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 16:08:25 ON 20 DEC 2005
L1             STRUCTURE UPLOADED
L2              50 S L1
L3            1449 S L2 FULL

     FILE 'HCAPLUS' ENTERED AT 16:11:25 ON 20 DEC 2005
L4             102 S L3/THU
L5              34 S L4 AND PD < JULY 2002
L6               1 S L4 AND BELL, R?/AU
L7             101 S L4 NOT L6
L8               2 S L7 AND BESWICK, P?/AU
L9             100 S L4 NOT L8
L10             99 S L9 NOT L6
L11              1 S L10 AND GOSMINI, R?/AU

=> s l10 not l11
L12            98 L10 NOT L11

=> s l12 and grimes, r?/au
             557 GRIMES, R?/AU
L13            0 L12 AND GRIMES, R?/AU

=> s l12 and hamlett, c?/au
               2 HAMLETT, C?/AU
L14            0 L12 AND HAMLETT, C?/AU

=> s l12 and king, n?/au
             567 KING, N?/AU
L15            0 L12 AND KING, N?/AU
```

```
=> s l12 and patel, v?/au
          1058 PATEL, V?/AU
L16          0 L12 AND PATEL, V?/AU

=> s bell, r?/au and beswick, p?/au and gosmini, r?/au and grimes, r?/au and hamlett
          2688 BELL, R?/AU
            57 BESWICK, P?/AU
            16 GOSMINI, R?/AU
           557 GRIMES, R?/AU
             2 HAMLETT, C?/AU
           567 KING, N?/AU
          1058 PATEL, V?/AU
L17          0 BELL, R?/AU AND BESWICK, P?/AU AND GOSMINI, R?/AU AND GRIMES,
               R?/AU AND HAMLETT, C?/AU AND KING, N?/AU AND PATEL, V?/AU

=>
```